

## Higher Physical Fitness Regulates *In Vitro* Tumor Cell Growth in Older Adults with Treatment Naïve Chronic Lymphocytic Leukemia (CLL).

Andrea Sitlinger<sup>3</sup>, Michael A. Deal<sup>1,2</sup>, Erwin Garcia<sup>4</sup>, Dana K. Thompson<sup>5</sup>, Tiffany Stewart<sup>5</sup>, Grace A. MacDonald<sup>1,2</sup>, Nicolas Devos<sup>6</sup>, David Corcoran<sup>6</sup>, Janet S. Staats<sup>7</sup>, Jennifer Enzor<sup>7</sup>, Kent J. Weinhold<sup>7</sup>, Danielle M. Brander<sup>3</sup>, J. Brice Weinberg<sup>5</sup>, David B. Bartlett<sup>1,2\*</sup>

<sup>1</sup>Division of Medical Oncology, Duke University School of Medicine, Durham, NC, USA.

<sup>2</sup>Duke Molecular Physiology Institute, Duke University School of Medicine, Durham, NC, USA.

<sup>3</sup>Hematologic Malignancies and Cellular Therapy, Duke University School of Medicine, Durham, NC, USA.

<sup>4</sup>Laboratory Corporation of America Holdings, Morrisville, NC, USA

<sup>5</sup>Division of Hematology, Duke University School of Medicine and VA Medical Center, Durham, NC, USA.

<sup>6</sup>Duke Center for Genomic and Computational Biology, Duke University, Durham, NC, USA

<sup>7</sup>Division of Surgical Sciences, Duke University School of Medicine, Durham, NC, USA.

\*Corresponding Author:

David B. Bartlett, PhD

Department of Medicine

Division of Medical Oncology

Duke Molecular Physiology Institute

Durham, North Carolina 27701

Phone: (919) 684-0622

Email: [david.bartlett@duke.edu](mailto:david.bartlett@duke.edu)

Physical Fitness, NMR lipoprotein and inflammation; NGS exosomal miRNA; NK-cell phenotype

### Abstract

Chronic lymphocytic leukemia (CLL) is associated with physical dysfunction and low overall fitness that predicts poor survival following commencement of treatment. However, it remains unknown whether higher fitness in CLL patients provides anti-oncogenic effects. We identified ten fit (CLL-FIT) and ten less fit (CLL-UNFIT) treatment-naïve CLL patients from 144 CLL patients who completed a set of physical fitness and performance tests. Patient plasma was used to determine its effects on *in vitro* 5-day growth/viability of three B-cell cell lines (OSU-CLL, Daudi and Farage). Plasma exosomal miRNA profiles, circulating lipids, lipoproteins, inflammation levels, and immune cell phenotypes were also assessed. CLL-FIT was associated with fewer viable OSU-CLL cells at Day 1 ( $p=0.003$ ), Day 4 ( $p=0.001$ ) and Day 5 ( $p=0.009$ ). No differences between groups were observed for Daudi and Farage cells. Of 455 distinct exosomal miRNAs identified, 32 miRNAs were significantly different between groups. Of these, 14 miRNAs had  $\leq -1$  or  $\geq 1$  log<sub>2</sub> fold differences. CLL-FIT patients had 5 exosomal miRNAs with lower expression and 9 miRNAs with higher expression. CLL-FIT patients had higher HDL cholesterol, lower inflammation, and lower levels of triglyceride components (all  $p < 0.05$ ). CLL-FIT patients had lower frequencies of low-differentiated NKG2<sup>+</sup>/CD158a/b<sup>neg</sup> ( $p=0.015$  and  $p=0.014$ ) and higher frequencies of NKG2A<sup>neg</sup>/CD158b<sup>+</sup> mature NK-cells ( $p=0.047$ ). Absolute numbers of lymphocytes including CD19<sup>+</sup>/CD5<sup>+</sup> CLL-cells were similar between groups ( $p=0.359$ ). Higher physical fitness in CLL patients is associated with altered CLL-like cell line growth *in vitro*, and with altered circulating and cellular factors indicative of better immune functions and tumor control.

NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

## Introduction

Chronic lymphocytic leukemia (CLL) is the most prevalent adult leukemia in the USA [1, 2], with a median age at diagnosis of approximately 70 years [3, 4]. Median overall survival is approximately 10 years, with durations ranging from months to decades [5]. The presentation of CLL is diverse, and patients have a shorter life expectancy than age-matched healthy populations [6]. CLL increases the risk of secondary malignancies and autoimmune diseases, and infections are the leading cause of death [7-9]. At present, there is no survival benefit from immediate or early therapy prior to established treatment indications, and most patients have a period of observation before therapy initiation [10, 11]. During the treatment naïve period, patients with CLL can have low overall fitness and physical dysfunction, both of which predict poor survival following commencement of treatment [12]. To-date, we are aware of no studies that have assessed the role physical fitness has on underlying pathophysiological factors of CLL [13].

Higher physical fitness and physical activity levels for lymphoma patients are associated with improvements in therapy-related side effects, physical functioning, and quality of life [13-15]. Although the underlying mechanisms are not fully understood, these effects can be partly explained by systemic changes or differences in host pathways including metabolism, inflammation and immune function that promote a less carcinogenic milieu [16]. In healthy adults, increasing physical fitness following diet and exercise training can result in reduced *in vitro* growth of breast and prostate cancer cell lines using autologous serum [17, 18]. In contrast, others reported that breast cancer survivors' autologous serum did not alter *in vitro* cell line growth following a 6-month exercise program [19]. However, they found that after completion of a single acute session of exercise, autologous serum blunted *in vitro* growth of breast [19] and colorectal cancer cell lines [20]. In these studies, acute exercise was associated with a transient increase of IL-6, IL-8, and TNF $\alpha$ , but not for insulin, suggesting complex interactions of endocrine and inflammatory mediators on cell line growth *in vitro*. Since elevated levels of pro-inflammatory mediators and insulin pathways are hallmarks of certain cancers, including CLL [21-23], other physical fitness host pathways are also likely to be influencing cancer behavior *in vivo* [24].

The primary aim of our current study was to evaluate the role of high and low physical fitness plasma from treatment naïve CLL patients on the *in vitro* growth/survival of a CLL-like cell line (OSU-CLL) [25]. The secondary aim was to identify similarities and differences in (a) circulating factors and (b) mononuclear cell phenotypes associated with CLL pathology. We hypothesized that plasma from high physically fit CLL patients would reduce the growth/survival of OSU-CLL cells *in vitro*.

## Materials and Methods

**Patient Characteristics:** Ten physically fit (CLL-FIT) and 10 least physically fit (CLL-UNFIT) treatment naïve CLL patients matched by age (mean  $\pm$  SD: 67.8  $\pm$  10.8 yrs., range: 51 – 86 yrs.) and sex (5M/5F in each group) were assessed for this study. Study participants were identified from 144 CLL patients assessed for physical fitness and function during their regular clinical visits at the Duke Cancer Center between July 2017 and March 2018. Of these patients, 69 were confirmed treatment naïve and Rai Stage 0-1. All participants gave written informed consent, and the study was approved by the Duke University Medical Center Institutional Review Board.

**Clinical Characteristics:** Clinical indices were obtained from patient's medical records. These included the CLL-IPI score, calculated as previously described [26], disease duration, cytogenetics (i.e. standard karyotype and fluorescent in situ hybridization for CLL), IGHV mutation status, and CD38 expression. Plasma levels of soluble CD20 (sCD20) and intercellular adhesion molecule 1 (ICAM-1) were determined in duplicate using a human sandwich immunoassay according to the manufacturer's instructions (Meso Scale Discovery, Rockville, MD).  $\beta$ 2-microglobulin (B2M) was determined in duplicate using a commercially available ELISA (R&D Systems, Minneapolis, MN). The lower limits of detection (LLOD) were sCD20 (30.5 pg/mL), ICAM-1 (2.60 ng/mL), and B2M (0.132  $\mu$ g/mL). All samples had concentrations greater than the LLOD with the exception of sCD20 with 81% of samples above the LLOD. Complete blood counts (CBCs) and differentials were clinically assessed at the Duke Clinical Laboratory using an automated hematology analyzer (Sysmex, Lincolnshire, IL, USA).

**Physical Performance and Fitness:** Patients completed a short battery of standardized physical performance tests. These included the 6-minute walk test (6MWT), the short physical performance battery (SPPB), timed-up and go (TUG), and grip strength. Following completion of physical testing, patients completed two physical activity questionnaires – the Incidental and Planned Activity Questionnaire (IPAQ) and the Stanford Brief Activity Survey (SBAS). We measured height and weight before testing, and blood pressure and resting heart rate following 10 minutes of seated rest. The  $eVO_{2peak}$  (mL/kg/min) was calculated using a validated equation that incorporates 6MWT distance, resting heart rate, weight, sex, and age [27]. We stratified groups using  $eVO_{2peak}$  matched for age ( $\pm 3$  yrs.) and gender.

**Blood Sampling:** Approximately 20 mL of blood was collected into vacutainers containing either EDTA or heparin as an anti-coagulant. Blood was centrifuged at 3000 *x rpm* for 10 minutes at 4°C, and 3-4 mL of plasma, aliquoted, and immediately frozen at -80°C. From the remaining blood, mononuclear cells (PBMCs) were isolated using Ficoll-Hypaque (GE Life Sciences, PA) density centrifugation, and stored in aliquots of  $10 \times 10^6$  cells/mL in 90% fetal bovine serum (FBS) plus 10% DMSO, in the vapor phase of liquid nitrogen [28].

**Autologous Plasma Incubation with Cell Lines.** We acquired the OSU-CLL cell line, generated by EBV transformation, from the Byrd Lab at Ohio State University [25]. This cell line is characterized by CD5 positivity, mutated IGHV, trisomy 12 and trisomy 19, a non-complex karyotype and wild type p53 expression. Importantly, it is stable under extended periods of culture. In addition to the OSU-CLL line, we used two other B-cell lymphoma cell lines to assess potential similarities between cell growth and plasma characteristics. Specifically we used the Daudi (ATCC® CCL-213) and Farage (ATCC® CRL-2630) cell lines. The Daudi line is an EBV transformed Burkitt's lymphoma B-lymphocyte, while the Farage is an EBV transformed mature B-cell line from a patient with diffuse large cell non-Hodgkin's lymphoma. The Daudi line is CD19+, CD5<sup>neg</sup>,  $\beta$ 2-microglobulin negative, and the Farage line is CD19+, CD20+, CD5<sup>neg</sup>, HLA-DR+. Cells were thawed and grown for 7 days in complete medium (RPMI + 56 U/mL penicillin + 56  $\mu$ g/ml streptomycin + 2 mM L-glutamine) + 10% fetal bovine serum (FBS). Cells were then washed and resuspended at  $5 \times 10^5$  cells/mL in complete media + 10% FBS (Control), or had the FBS replaced with 10% autologous plasma. To determine whether the differences between controls (serum) and autologous plasma might be affected by anticoagulant agents, we also incubated serum (collected at the same time for a different study) from four patients with the OSU-CLL line. Correlations between autologous

serum and plasma were  $r=0.85$  (data not shown). At baseline and every 24 hours for 5 days, cell density was measured in duplicate by both hemocytometer counting and the cell-counting feature of the Attune NxT flow cytometer (ThermoFisher). Live viable cells were quantified as Annexin<sup>neg</sup>/PI<sup>neg</sup>, early apoptotic as Annexin<sup>pos</sup>/PI<sup>neg</sup>, and late apoptotic/necrotic as Annexin<sup>pos</sup>/PI<sup>pos</sup> using manufacturer guidelines (BD Biosciences) using the Attune NxT flow cytometer.

**Exosomal miRNA.** Plasma (500  $\mu$ L) was briefly thawed at 37°C and filtered to exclude particles  $>0.8 \mu$ m for isolation of exosomal RNA using the Qiagen exoRNeasy midi kit (Qiagen, Hilden, Germany). We then purified exosomes before RNA extraction was completed using Qiagen miRNeasy chloroform based technology. RNA quantity and quality was quantified on a NanoDrop 2000 spectrophotometer (ThermoFisher). For sequencing, 5  $\mu$ L of each exosomal RNA extract was used to generate a miRNA library using principals and methods similar to previously described [29-31]. The libraries were generated using the QIAseq miRNA Library kit (Qiagen). This kit uses modified adapters that efficiently ligate to microRNAs generated by Dicer processing. It also uses 12 bp Unique Molecular Indices (UMIs) to tag each miRNA at an early stage, eliminating PCR and sequencing bias. During library prep, libraries were indexed using a single 6 bp indexing approach allowing for multiple libraries to be pooled and sequenced on the same sequencing flow cell of an Illumina sequencing platform. Before pooling and sequencing, we assessed fragment length distribution and overall library quality on an Agilent Fragment Analyzer instrument (Agilent Technologies). Concentrations of each library were assessed using a Qubit fluorometer (ThermoFisher). We then pooled 20 libraries in an equimolar ratio and sequenced on a NextSeq High Output flow cell. To sequence the 12 bp UMIs that were used to tag each miRNA, sequencing was completed at a 75 bp single read. Approximately sixteen million reads were generated for each sample, and a total of 455 distinct miRNAs identified.

**miRNA Analyses.** smRNA-seq data was processed using the TrimGalore toolkit [32] that employs Cutadapt [33] to trim low quality bases and Illumina sequencing adapters from the 3' end of the reads. Only reads that were 18 to 28 nt in length after trimming were kept for further analysis. Reads were mapped to the hg19 version of the human genome using the Bowtie alignment tool [34]. Reads were kept for subsequent analysis if they map to no more than 13 genomic locations. Gene counts were compiled using custom scripts that compare mapped read coordinates to the miRBase [35] microRNA database. Reads that match the coordinates of the known mature microRNAs were kept if they perfectly matched the coordinates of the miRNA seed while not varying by more than 2 nt on the 3' end of the mature miRNA. Only mature miRNAs that had at least 10 reads in any given sample were used in subsequent analysis. Normalization and differential expression were carried out using the DESeq2 [36] Bioconductor [37] package from the R statistical programming environment. Normalization was performed using the 'poscounts' approach to eliminate systematic differences across the samples.

**Flow Cytometry:** PBMCs were partly thawed in a 37°C water bath, then completely thawed using the dropwise method and washed in 37°C thaw buffer (RPMI + 10% FBS + 1% penn/strep + 1% L-Glutamine + 25U/ $\mu$ L Benzonase). Cells were counted and resuspended at  $10 \times 10^6$  cells/mL in Dulbecco's PBS (DPBS), and 100  $\mu$ L aliquoted into FACS tubes. Cells were first stained with 0.1  $\mu$ L of the viability dye Zombie Aqua (BioLegend, CA),

before blocking Fc receptors (Human TruStain FcX, BioLegend), followed by complete combinations of the following antibodies. NK-cell tubes contained 0.63 µg/mL CD3 BUV395 (Clone SK7; BD Bioscience), 0.16 µg/mL CD56 BB700 (Clone NCAM16.2; BD Bioscience), 0.25 µL NKG2A PE (Clone REA110; Miltenyi Biotec, MD), 2.5 µL NKG2C PE-Vio770 (Clone REA205; Miltenyi Biotec), 10 µg/mL NKG2D BB515 (Clone 1D11; BD Bioscience), 5 µg/mL CD244 BV421 (Clone 2-69; BD Bioscience), 5 µL CD158a APC-Vio770 (Clone REA284; Miltenyi Biotec), and 5 µg/mL CD158b APC (Clone DX27; BioLegend). Monocyte tubes contained 1.25 µg/mL CD14 BUV805 (Clone M5E2; BD Bioscience) and 1.25 µg/mL CD16 BUV395 (Clone 3G8; BD Bioscience). T-cell and B-cell tubes contained 1 µg/mL CD3 Pacific Blue (Clone UCHT1; BD Bioscience), 1 µg/mL CD4 PE (Clone OKT4; BioLegend), 10 µg/mL CD8 FITC (Clone OKT8; ThermoFisher, MA), 1.5 µg/mL CD19 APC-Cy7 (Clone HIB19; BioLegend), and 3 µg/mL CD5 APC (Clone UCHT2; BioLegend). We titrated all antibodies prior to assessing samples, and used single color and flow minus one (FMOs) tubes for compensation. Cells were incubated for 30 minutes on ice in the dark before being fixed with 1% paraformaldehyde (Sigma Aldrich). Cells analyzed on either a BD LSR Fortessa (NK-cell and monocytes) equipped with 4 lasers or a BD FACS Canto II (T-cell and B-cells) equipped with 3 lasers. All analyses were completed after acquisition using FCS Express v6 (DeNovo Software, CA).

**Nuclear Magnetic Resonance (NMR) Spectroscopy.** Plasma (600 µL) stored at -80°C was analyzed by NMR at LabCorp (Morrisville, NC, USA) as single batch. NMR spectra were acquired on a Vantera® Clinical Analyzer as previously described [38]. The concentration of GlycA, a marker of systemic inflammation [39, 40], was calculated from NMR signal amplitudes of highly mobile protons of *N*-acetylglucosamine residues located on the carbohydrate side-chains of circulating acute phase proteins (e.g., α1-acid glycoprotein, haptoglobin, α1-antitrypsin, α1-antichymotrypsin, and transferrin). Concentrations of lipids, lipoprotein particles, apolipoproteins, and particle sizes were measured using advanced proprietary deconvolution algorithm (LP4) which provides better resolution of subclasses compared to previous algorithms [38, 41, 42]. We calculated the Lipoprotein Insulin Resistance Index (LP-IR) from NMR-measured lipoprotein particle sizes (TRL, LDL and HDL) and particle concentrations (very large TRL + large TRL, small LDL, large HDL). LP-IR scores range from 0 (least insulin resistant) to 100 (most insulin resistant) [38, 41]. Valine, leucine and isoleucine (BCAAs) and their sum (total BCAA) were quantified as previously described [43]. Glucose, glycine and alanine were measured using the LP4 algorithm.

**Statistical Analyses.** We conducted patient characteristics, NMR data, and immune data analyses using SPSS version 23.0 (IBM, Armonk, NY, USA). Normality was assessed using Kolmogorov-Smirnov analysis. For variables violating normality, we used non-parametric analyses. Comparisons of variables were completed using Independent T-tests, Mann-Whitney U tests, and Chi-square analyses were used for categorical variables. Spearman correlations were conducted between variables as measures of associations. For analyses of cell line incubations with autologous plasma, a repeated linear mixed model was used to model both the numeric and percentage changes in cell growth. The model included main effects and interaction effects for time (Days 0, 1, 2, 3, 4, and 5) and group (CLL-FIT and CLL-UNFIT). Contrasts were used *a priori* to determine overall effects for time within each group, where significant effects for time occurred, and differences between groups at each



time point. Results are presented with standard deviations (SD), 95% confidence intervals (CI) and effect sizes calculated as Cohen's D ( $d$ ). Statistical significance was accepted as  $p \leq 0.05$ .

## Results.

**Group Demographics, Clinical Measures, Physical Fitness and Function.** Groups were clinically similar for staging, disease duration, and cytogenetics (all  $p > 0.1$ ) (Table 1). CLL-UNFIT patients were heavier ( $p = 0.049$ ), and had a higher BMI ( $p = 0.013$ ). CLL-FIT had higher cardiorespiratory fitness based on  $eVO_{2peak}$  ( $p < 0.001$ ), which was characterized by CLL-FIT completing 20% greater 6MWT distance ( $p = 0.027$ ) and 18% better on the SPPB ( $p = 0.012$ ). Both groups had similar grip strengths, TUG times, and similar self-reported exposure to physical activity levels (all  $p > 0.05$ ). CLL-UNFIT had higher neutrophil counts ( $p = 0.046$ ), while lymphocyte ( $p = 0.517$ ) and monocyte counts ( $p = 0.694$ ) were similar in both groups. No differences were observed between groups for absolute numbers of CD19+/CD5+ CLL B-cells ( $p = 0.314$ ), CD4+ ( $p = 0.169$ ) or CD8+ ( $p = 0.438$ ) T-cells. Similarly, no differences were observed for CD14+/CD16<sup>neg</sup> ( $p = 0.861$ ), CD14+/CD16+ ( $p = 0.635$ ), or CD14+/CD16++ ( $p = 0.598$ ) monocytes (data not shown).

**Cell Line Growth with Autologous Plasma.** Cell growth was quantified by both the average cell count per well from duplicate wells and the percentage change of cell counts over time in culture (Figure 1). Results are representative from ten CLL-FIT and nine CLL-UNFIT patients. There was a significant main effect for time ( $F(5, 85) = 615.0$ ;  $p < 0.001$ ;  $\eta^2 = .973$ ) and a group x time interaction ( $F(5, 85) = 5.17$ ;  $p < 0.001$ ;  $\eta^2 = .233$ ) for viable OSU-CLL cell numbers (Fig. 1A). At Day 1 ( $p = 0.003$ ), Day 4 ( $p = 0.001$ ) and Day 5 ( $p = 0.009$ ) CLL-UNFIT had 16%, 12%, and 15.5% more cells than CLL-FIT did, respectively. Similarly, there was a significant main effect for time ( $F(4, 68) = 88.1$ ;  $p < 0.001$ ;  $\eta^2 = .838$ ) and a group x time interaction ( $F(4, 68) = 6.57$ ;  $p < 0.001$ ;  $\eta^2 = .279$ ) for viable OSU-CLL percentage change from the previous day (Fig. 3B). Compared to CLL-FIT, at Day 1 ( $p = 0.010$ ) and Day 4 ( $p = 0.016$ ) CLL-UNFIT had a 42.5% and 7.7% greater increase in previous day cell numbers, but a 16.5% lower increase in previous cell numbers at Day 2 ( $p = 0.042$ ). There was a significant main effect for time for Daudi cell numbers (Fig. 3C:  $F(5, 85) = 770.0$ ;  $p < 0.001$ ;  $\eta^2 = .980$ ) and percentage change (Fig. 3D:  $F(5, 85) = 192.2$ ;  $p < 0.001$ ;  $\eta^2 = .923$ ) but no group x time interactions. Similarly, there was a significant main effect for time for Farage cell numbers (Fig. 3E:  $F(5, 85) = 165.9$ ;  $p < 0.001$ ;  $\eta^2 = .907$ ) and percentage change (Fig. 3F:  $F(5, 85) = 16.2$ ;  $p < 0.001$ ;  $\eta^2 = .489$ ) but no group x time interactions.

**Exosomal microRNA Profiles.** RNAseq revealed a total of 455 distinct exosomal miRNA profiles isolated from patient plasma samples (Supplementary Table 1). To assess similarities and differences in exosomal miRNA profiles between CLL-FIT and CLL-UNFIT patients, we employed a hierarchical clustering method. As shown in Fig. 2A, exosomal miRNA clusters in CLL-FIT vs. CLL-UNFIT differed dramatically, characterized by 32 exosomal miRNAs having a Wald Test  $p$ -value of  $\leq 0.05$  (Supplementary Table 2). Of these, 14 miRNA profiles had  $\leq -1$  or  $\geq 1$  log<sub>2</sub> fold difference between groups (Fig. 2B). Relative to CLL-UNFIT, CLL-FIT had five miRNAs (miR-378a-3p, miR-32-5p, miR-29c-3p, miR-183-5p, and miR-576-5p) with lower expression (blue dots), and nine miRNAs (miR-130b-5p, miR-1301-3p, miR-4433b-3p, miR-383-5p, miR-328-3p, miR-4433b-5p, miR-324-3p, miR-6772-3p, and miR-1296-5p) with higher expression (red dots). Using miRNA target gene prediction

software (miRDB: <http://mirdb.org/index.html>), we determined which target genes relevant to CLL would be affected by the differential expression of exosomal miRNAs (Supplementary Table 3). There was a pattern for the miRNAs expressed more in CLL-UNFIT to target NOTCH, BCL2, and cyclin signaling.

**NK-Cell Immunophenotype.** Fig. 3A (CLL-FIT) and Fig. 3B (CLL-UNFIT) show representative flow cytometry plots for the frequencies of CD3<sup>neg</sup>/CD56<sup>+</sup> NK-cells on total lymphocytes. CLL-FIT patients had a trend for lower absolute numbers of NK-cells (Fig. 3C:  $p=0.07$ ) and lower frequencies of CD3<sup>neg</sup>/CD56<sup>+</sup> NK-cells (Fig. 3D;  $p=0.035$ ). Groups were similar for the frequencies of CD56<sup>dim</sup> (Fig. 3E:  $p=0.348$ ) and CD56<sup>bright</sup> (Fig. 3F:  $p=0.437$ ) NK-cells. CLL-FIT had a lower frequency of Low-Differentiated NKG2A<sup>+</sup>/CD158a<sup>neg</sup> (Fig. 3G:  $p=0.015$ ) and NKG2A<sup>+</sup>/CD158b<sup>neg</sup> (Fig. 3H:  $p=0.014$ ) NK-cells. We noted no differences for Medium-Differentiated NKG2A<sup>+</sup>/CD158a<sup>+</sup> (Fig. 3I:  $p=0.196$ ) or NKG2A<sup>+</sup>/CD158b<sup>+</sup> (Fig. 3J:  $p=0.256$ ) NK-cells. CLL-FIT had a higher frequency of Terminally-Differentiated NKG2A<sup>neg</sup>/CD158b<sup>+</sup> (Fig. 3L:  $p=0.047$ ) but not NKG2A<sup>neg</sup>/CD158a<sup>+</sup> (Fig. 3K:  $p=0.09$ ) NK-cells. Of the NK-cell surface marker expression (MFI), only CD158a was higher in CLL-FIT ( $257 \pm 32$  v  $229 \pm 24$ ,  $p=0.046$ ), with no differences for CD158b ( $257 \pm 113$  v  $217 \pm 39$ ,  $p=0.301$ ), NKG2A ( $769 \pm 425$  v  $762 \pm 134$ ,  $p=0.960$ ), NKG2C ( $299 \pm 58$  v  $264 \pm 22$ ,  $p=0.093$ ), NKG2D ( $1293 \pm 220$  v  $1331 \pm 133$ ,  $p=0.651$ ), or CD244 ( $141 \pm 48$  v  $120 \pm 5$ ,  $p=0.190$ ), data not shown.

**NMR Measured Lipids, Lipoproteins (LipoProfile<sup>®</sup>), and Inflammatory Profiles.** Table 2 shows group differences for pertinent NMR measures. CLL-FIT had lower GlycA concentrations ( $p=0.014$ ) and a lower lipoprotein derived insulin resistance score (LP-IR:  $p=0.007$ ). CLL-FIT had lower concentrations of total triglycerides ( $p=0.025$ ) and triglyceride rich lipoproteins (TRLs;  $p=0.016$ ). CLL-FIT had lower total levels of TRL particles (TRLP:  $p=0.046$ ), large TRLP ( $p=0.011$ ) and very small TRLP ( $p=0.044$ ). CLL-FIT had smaller mean TRL particle size ( $p=0.027$ ). CLL-FIT had lower levels of TRL cholesterol ( $p=0.034$ ), higher HDL cholesterol ( $p=0.040$ ), and higher concentrations of large HDL particles ( $p=0.043$ ). Complete NMR analyses are presented in Supplementary Table 4.

**Correlations Between miRNAs, Immune Cells and Lipids.** CLL-UNFIT patients had higher expression of miR-29c that was associated with higher WBC ( $r=.558$ ,  $p=0.011$ ) and lymphocyte counts ( $r=.555$ ,  $p=0.011$ ). CLL-FIT patients had higher expression of miR130b-5p that was associated with lower absolute counts of CD56<sup>bright</sup> ( $r=-.493$ ,  $p=0.027$ ) and a trend for CD56<sup>dim</sup> ( $r=-.434$ ,  $p=0.056$ ) NK-cells. Additionally, higher expression of miR-130b was associated with lower frequencies of low-differentiated NKG2A<sup>+</sup>/CD158a<sup>neg</sup> ( $r=-.544$ ,  $p=0.013$ ) and highly differentiated mature NKG2A<sup>+</sup>/CD158b<sup>neg</sup> NK-cells ( $r=-.461$ ,  $p=0.041$ ). Higher expression of miR-130b was associated with higher levels of large HDL particles ( $r=.489$ ,  $p=.029$ ), lower insulin resistance ( $r=-.498$ ,  $p=0.025$ ), lower large TRLP levels ( $r=-.497$ ,  $p=0.026$ ) and smaller TRL lipoprotein size ( $r=-.451$ ,  $p=0.046$ ). Finally, higher expression of miR-4433b-3p was associated with higher frequencies of highly differentiated NKG2A<sup>neg</sup>/CD158a<sup>+</sup> ( $r=.459$ ,  $p=0.042$ ) and a trend for higher NKG2A<sup>neg</sup>/CD158b<sup>+</sup> NK-cells ( $r=.390$ ,  $p=0.089$ ).

## Discussion

For the first time, to our knowledge, we examined the role of physical fitness on *in vitro* malignant cell line growth in older adults with treatment naïve chronic lymphocytic leukemia. Incubation of patient derived plasma with cell lines was associated with differential growth patterns of a CLL-like cell line (OSU-CLL), but not related lymphoma cell lines (Daudi and Farage) suggesting that components in the plasma are specific for the growth of CLL-like cells. Using next generation sequencing, we identified 32 distinct exosomal miRNA profiles with significantly different expression profiles, of which 14 were differentially expressed with a log<sub>2</sub> fold difference  $\geq 1$  or  $\leq -1$ . Many of the exosomal miRNAs that were higher in CLL-UNFIT patients' plasma were associated with promoting tumor and immune suppression suggesting CLL cells could be removing them from cells in exosomes. Higher fitness was associated with a greater frequency of mature NKG2A<sup>neg</sup>/KIR<sup>+</sup> NK-cells. We also identified miRNAs that are associated with lipid homeostasis – a major source for energy and cell signaling unique to CLL cells [44, 45]. Using NMR spectroscopy, we discovered that higher fitness is associated with higher HDL cholesterol, lower triglyceride species (including large and very small triglyceride rich lipoprotein particle levels), triglyceride rich lipoprotein cholesterol levels, and smaller triglyceride rich lipoprotein particle sizes. This cross-sectional analysis for the first time, to our knowledge, shows that physical fitness and function may play a role in the underlying biology of CLL.

### **Cell Growth in Autologous Plasma**

Our study is the first that we are aware of to demonstrate that serological differences in physically fit CLL patients are associated with slower *in vitro* growth of the CLL-like cell line OSU-CLL. Higher physical fitness is associated with optimal nutritional intake and greater exposure to physical activity and exercise. Following a single bout of exercise in healthy humans, sera/plasma reduces the growth of colorectal, breast, and prostate cancer cell lines, suggesting that exercise increases circulating factors capable of slowing the growth of tumor cells [19, 20, 46]. In mice, 30-days of exercise training reduced lung, melanoma, and liver tumor burden through an IL-6 sensitive and NK-cell mediated mechanism [47]. After each bout of exercise, there are transient increases then decreases upon exercise completion of circulating concentrations of IL-6, and other pro-inflammatory, immunoregulatory cytokines [19, 20, 46-48]. However, resting (i.e. no acute exercise) sera from breast cancer survivors did not alter the growth of breast cancer cell lines following a 6-month exercise intervention [19]. Exercise training reduced circulating concentrations of IL-6 and TNF $\alpha$ , suggesting a more complex role of inflammatory mediators that affects the growth of cell lines *in vitro* [19]. Contrary to findings by Dethlefsen *et al.* [19], we observed lower levels of the chronic inflammatory marker GlycA in CLL-FIT patients and slower *in vitro* cell growth. GlycA is robustly modifiable by exercise training and is lower in those with higher cardiorespiratory fitness [49, 50]. As such, the role inflammation plays on cancer cell growth is complex, and the inflammatory response to exercise which promotes higher physical fitness are equally complex in the cancer setting.

### **Potential Circulating Factors Associated With Tumor Cell Growth In Vitro**

In an attempt to understand reduced OSU-CLL growth by CLL-FIT plasma, we assessed mediators with known roles in CLL pathophysiology that might be modified by increasing physical fitness. Among the many potential mediators, two include lipids/lipoproteins [44, 45] and exosomal miRNAs [51, 52].



**Exosomal miRNAs.** The role of both intracellular and extracellular (i.e. cell free and packaged in extracellular vesicles) miRNAs in CLL have revealed at least 10-20 miRNAs associated with varying disease characteristics [51-57]. Exosomes are the smallest known extracellular vesicles (50-100 nm) with distinct biochemical properties that carry cellular components, such as proteins, peptides, lipids, mRNA, and miRNAs [58]. miRNAs are small (~18-28 nt) non-coding RNAs that bind to the specific 3' UTR of their target mRNA, inducing translational repression, mRNA decapping and deadenylation [59, 60]. miRNAs are transferred from cell to cell in abundance by tumor-derived exosomes and considered as potential disease biomarkers [61, 62]. Exosomes are constitutively secreted in response to B-cell receptor activation and stress by CLL cells. The roles of these miRNAs include promotion of CLL cell survival by (a) altering transcription in the CLL cell, (b) altering functions of cells of the tumor microenvironment, and (c) altering effector functions of immune cells such as CD8+ T-cells and NK-cells, and thus promoting immune evasion and chronic immune suppression [61, 63, 64].

**miRNAs and Physical Fitness.** Thus far, only one study that we are aware of has assessed differences in exosomal miRNA expression between sedentary (N=5) and physically fitter (N=5) older adults [65]. In the fitter group, Nair and colleagues found that exosomal miR-486-5p, miR-215-5p, and miR-941 were upregulated, but that miR-151b was downregulated compared to that in the control group – none of which we observed significant differences for in our study [65]. Although the ages of the Nair study participants were similar to those in our study, their subjects were all male and differences between their groups and our groups for fitness were less (Nair = 37% v our 27%) and for group's BMI was greater (Nair = 10% v our 26%). With this, and the addition of CLL, it is not possible to compare our results other than to appreciate that physical fitness is likely associated with differential expression of exosomal miRNAs in older adults. As such, we discuss our results in terms of known tumor promotion and immune suppression strategies of differentially expressed miRNAs.

**miRNAs and Cell Survival.** Compared to healthy adults, CLL patient exosomes have higher expression of miR-29c that is associated with elevated white blood cell and lymphocyte counts [52, 63, 66]. Here, we show that CLL-UNFIT patients have higher expression of exosomal miR-29c, and that higher expression is associated with higher WBC and lymphocyte counts. In patients with unfavorable prognostic markers, miR-29c is downregulated inside (rather than outside in exosomes) CLL cells [67]. Compared to healthy donor B-cells, normal B-cells from CLL patients have similar expression of miR-29 [63]. This suggests that CLL cells are preferentially expelling miR-29 inside exosomes. miR-29c targets multiple NOTCH1, BCL2 and cyclin related mRNAs, post-transcriptionally repressing translation and impacting regulatory control of cell apoptosis, growth and proliferation. Additionally, miR-15a ( $p=0.0529$ ) and miR-16-1 ( $p=0.0304$ ) were both approximately 2-fold lower in CLL-FIT patient exosomes. These exosomes are two of the first to be identified as regulators of CLL cell survival [68]. Both promote BCL2 repression and induce apoptosis in leukemia cell lines, and as such are downregulated inside CLL cells. CLL cells are likely expelling miR-29c, and other negative regulators, to promote their survival and growth. Although lower physical fitness might be associated with more secretion of miR-29c from CLL cells, it is plausible that higher fitness is causing more *in vivo* uptake of exosomes containing miR-29c. However, it is not clear from which cells these miRNAs would originate.

**miRNAs and Immune Function.** Many tumor-originating exosomal miRNAs function by suppressing the normal immune system's ability to recognize and kill tumor cells [69, 70]. Of these, exosomal miR-29c, miR-378,

miR-183 and miR-130b were differentially expressed in our two groups. miR-29c, miR-378, and miR-183 each target NK-cell and some CD8+ T-cell functions, including IFN $\gamma$  production, granzyme B formation and activatory receptor expression [71-75]. As such, it is plausible that more CLL derived exosomal miR-29c, miR-378, and miR-183 are being delivered to more NK-cells and CD8+ T-cells observed in CLL-UNFIT patients. Higher miR-130b, the only one with higher expression in CLL-FIT patients, correlated with lower absolute numbers and frequencies of NK-cells – a characteristic noted in healthy adults compared to CLL [76, 77]. Although it is unclear if miR-130b influences NK-cells, it has been shown to disrupt the CLL mediated polarization of immunosuppressive macrophages [78]. In mice, miR-130b promotes macrophage differentiation into a more favorable M1 phenotype, while sera from CLL patients has been noted to result in induction of monocyte differentiation towards an M2 macrophage phenotype [78, 79]. Further studies are required to elucidate whether higher physical fitness is promoting immune surveillance by selectively increasing (i.e. miR-130b) and lowering (i.e. miR-29c, miR-378 and miR-183) exosomal miRNAs that influence effector immune cell functions.

Of the remaining miRNAs expressed more in CLL-FIT patient exosomes, less is known for CLL. In chronic myelogenous leukemia (CML) cells, increasing expression of miR-328-3p and miR-4433b reduces blast cell survival and impairs cell growth [80, 81]. Exosomal miR-32-5p activates the PI3K/Akt pathway and suppresses PTEN in solid tumor cells [82].

Taken together, differential expression of exosomal miRNAs plays an important role in the pathophysiology of CLL [51, 56]. We provide a novel insight into possible mechanisms by which physical fitness might influence CLL biology. Most of the exosomal miRNAs that are higher in CLL-UNFIT target NOTCH, Cyclins, and BCL2 signaling (Supplementary Table 3). These pathways are typically overexpressed in CLL and offer favorable prognosis when suppressed or inhibited. As such, CLL-UNFIT cells appear to be selectively expelling tumor-suppressing miRNAs in exosomes [83], and these exosomes likely do not bind efficiently with malignant cells or deliver their contents to neighboring tumor cells [61]. This is particularly evident given that CLL-UNFIT plasma is associated with increased growth of a CLL-like cell line while having similar mean CLL absolute cell numbers as CLL-FIT. Consequently, understanding the role of physical fitness on exosomal miRNA functions may lead to novel understandings of CLL progression and immune evasion.

**Lipid/Lipoprotein Homeostasis.** There are much data to suggest that in overweight and obese older adults, regular exercise and/or weight loss can affect health outcomes by improving profiles of lipids and lipoproteins [84]. Here, CLL-FIT patients had higher levels of HDL cholesterol, and lower triglycerides and triglyceride rich lipoproteins – levels consistent with better physical fitness [85]. However, compared to healthy adults, CLL levels of cholesterol, HDL and LDL are lower [86, 87]. In addition, these lipids are lowered more as disease stage increases [86]. McCaw and colleagues, using an *in vitro* pseudofollicle model of CLL proliferation, suggest that lipids and LDLs are preferentially utilized by CLL cells for cell signaling functions [44]. Specifically, LDL mediated amplification of STAT3 phosphorylation and cholesterol dense lipid rafts uniquely improve CLL cell survival and increase proliferation [44]. As such, preventing this CLL-lipid process should negatively regulate lipid metabolism in CLL cells. Indeed, lipid-lowering medications confer longer time to first treatment and improved CLL patient survival [45, 88]. Interestingly, we show here that higher exosomal miR-130b expression is associated with better lipid profiles suggesting that miR-130b has a role in CLL lipid homeostasis. Indeed,

miR-130b is a potential regulator of lipid homeostasis, targeting lipid oxidation and LDL receptor expression [89, 90]. That said, dyslipidemia and hypercholesterolemia also likely have complex roles in the pathogenesis of CLL, but these are not fully understood [91, 92]. Lowering these lipids and lipoproteins by either medications, diet, or exercise (before CLL cells can utilize them) could modulate CLL cell growth, and warrants further investigation.

**The Immune System.** Higher physical fitness and regular physical activity in older age maintains and improves important immune functions associated with reduced risks of infections, cancer, and chronic diseases [93-97]. Indeed, older fitter and healthier adults have T-cell and B-cell characteristics more similar to adults many years younger [98, 99], while NK-cells have improved function in those with increased physical fitness [24, 47]. Compared to healthy adults, newly diagnosed and treatment naive CLL is associated with higher absolute numbers of CD4+ and CD8+ T-cell, and NK-cells [76, 77]. In CLL, NK-cell and T-cell expansion is driven by repeated cycles of replication due to increased infections [77]. CLL NK- and T-cells are characterized by increased inhibitory receptor expression (e.g. PD-1, Tim3, and CTLA-4) indicative of an “exhausted” phenotype, contributing to poor resolution of infections [100]. We show that CLL-FIT patients have lower frequencies of NK-cells, and lower absolute numbers of CD8+ and CD4+ T-cells (albeit non-significantly), and NK-cells—all similar to observations in healthy adults [76, 77]. Further, CLL reduces NK-cell tumor cytotoxicity, reduces expression of activatory NK-cell receptors, and increases inhibitory NK-cell receptor expression [76, 101]. We show in the current study that CLL-FIT patients have a lower frequency of inhibitory positive/activatory negative (i.e. NKG2A<sup>+</sup>/KIR<sup>neg</sup>) NK-cells and higher frequency of fully competent mature inhibitory negative/activatory positive (i.e. NKG2A<sup>neg</sup>/KIR<sup>+</sup>) NK-cells that are better capable of recognizing and killing tumor cells [102]. Since we did not observe absolute number differences in malignant cells, it may be that CLL NK-cells are less responsive to physical fitness. Alternatively, it may be that over several years, CLL cells from CLL-FIT patients have not been exposed to as many infections that drive increased immune cell numbers. Another possible explanation for this could be that CLL-UNFIT patients have more CLL cells residing in primary and secondary lymphoid tissues. Although our groups were similarly matched for disease stage, increasing lymphoid tissue size is a characteristic of disease progression due to the accumulation of malignant CLL cells. Unfortunately, we were unable to determine whether there were lymph node or splenic size differences in our groups, but given the variation in absolute lymphocyte counts in the blood it is likely that there is also large variation in the lymphoid tissue. A potential way to assess this is through measuring lymphocyte counts before and immediately after an acute bout of moderate-vigorous intensity exercise. An acute bout of exercise temporarily increases circulating blood lymphocyte counts, before counts return to normal in the hours following exercise completion [93]. Lymphocytes move into the blood from the marginated pool and secondary lymphoid tissues allowing quantification of total body lymphocyte counts, rather than just those in the blood [103]. Perry *et al.* showed that in four CLL patients’ lymphocyte counts increased by 40% following exercise (resting:  $18.7 \pm 6.6 \times 10^6/\text{mL}$  to immediately post exercise:  $26.3 \pm 11.4 \times 10^6/\text{mL}$ )[104]. With no changes for CD4+ T-cell counts, the majority of the increase was CD8+ T-cells, NK-cells and CD19+ B-cells. Further studies are required to determine the role of physical fitness on normal immune cell phenotype and function in CLL.

### **Limitations and Future Directions.**

Our study is not without limitations. Our sample size was small and as such limits our interpretations of the data. Larger sample sizes should be assessed to confirm our findings. We used autologous plasma and fetal bovine serum (control) for tumor cell incubation assays. We did this to ensure the composition of the plasma used for NMR and RNAseq were similar to the cell assays. Although we tried to encourage all patients to perform their best and to exert maximal efforts in the physical assessments, we can never be certain that this was done, but differences in other functional measures did not reflect this. With significant differences in SPPB and better (albeit non-significant) values for TUG and normalized grip we are confident our groups are representative of the fitter and least fit CLL patients. We did not explore comprehensive phenotypes or functions of T-cells or B-cells. As such, it remains unclear whether physical fitness is associated with distinct subsets of T- and B-cells that may be critical to CLL progression. Whether the differences in NK-cells reflect better tumor control mechanisms is also unclear. There are two important future directions for our research: (a) confirm our findings in a larger cohort with more comprehensive physiological and biological phenotyping, with inclusion of more functional measures of tumor control, including culture of autologous malignant B-cells, and (b) attempt to change the physical fitness of CLL patients and determine which of our biological measures changes accordingly.

### **Conclusions.**

In treatment naïve CLL, the CLL-like cell line (OSU-CLL) cultured *in vitro* with plasma from patients with higher physical fitness results in less growth/survival as compared to cells cultured in plasma from CLL patients with lower physical fitness. Higher fitness is associated with greater frequency of mature NK-cells, lower triglyceride concentrations, and differentially expressed miRNAs in plasma exosomes. The combination of these factors likely reflects improved health outcomes associated with being physically fit. Importantly, we noted that physical fitness is not associated with worsening CLL outcomes, and suggest that being fitter imparts a reduced risk of diabetes (lower insulin resistance), less cardiovascular disease (lower GlycA inflammation), and potentially less secondary malignancies and infections (higher frequency of mature NK-cells).

### **Funding.**

This work was supported by a Duke Claude D. Pepper Older Americans Independence Center Pilot Study Award (National Institutes of Health, National Institute on Aging P30-AG028716), National Institutes of Health, National Heart, Lung, and Blood Institute T32 grant (T32HL007057), the Durham Veterans Affairs Medical Center Research Service, an American Society of Hematology Scholars Award, and the Duke University Center for AIDS Research NIH funded program (P30 AI 64518).

### **Author Contributions.**

DBB, DMB, JBW and AS conceived and designed the study and experimental approach. EG completed the NMR spectroscopy and data analysis. MAD, DKT, and TS identified and completed physical testing on the patients. DBB and GM performed the cell growth assay. ND and DC completed the RNAseq and analysis. JS, JE, KW helped design and analyze the flow cytometry data. All authors contributed to critical revisions and approval of the final manuscript.

## Acknowledgements.

The research team acknowledges the support of the Duke Cancer Center and the support provided by nurses and clinical staff during the execution of the study. We also acknowledge Prof. John Byrd from the Ohio State University for providing us with the OSU-CLL cell line. Finally, we appreciate the participants who kindly gave up their time to take part in this study.

## Abbreviations

6MWT: 6-minute walk test  
BCAA: branch chain amino acid  
CBC: complete blood count  
CD: cluster of differentiation  
CLL: Chronic Lymphocytic Leukemia  
CLL-IPi: Chronic Lymphocytic Leukemia – International Prognostic Index  
DMSO: Dimethyl sulfoxide  
DPBS: Dulbecco's phosphate buffered saline  
EBV: Epstein Barr Virus  
EDTA: Ethylenediaminetetraacetic acid  
eVO<sub>2</sub>peak: estimated peak volume of oxygen consumption  
FBS: fetal bovine serum  
FFA: Free Fatty Acids  
FMO: flow minus one  
HDL: high-density lipoprotein  
ICAM-1: Intercellular Adhesion Molecule 1  
IFN: interferon  
IGHV: immunoglobulin heavy chain variable region genes  
IL: interleukin  
IPAQ: Incidental and Planned Activity Questionnaire  
KIR: Killer immunoglobulin-like receptor  
LDL: low-density lipoprotein  
LP-IR: Lipoprotein Insulin Resistance Index  
miRNA: micro-RNA  
NK-cell: Natural Killer Cell  
NKG2: CD94/NK group 2 member  
NMR: nuclear magnetic resonance  
OSU-CLL: Ohio State University-Chronic Lymphocytic Leukemia  
PBMC: peripheral blood mononuclear cell  
PI: propidium iodide  
RNA: ribonucleic acid  
RPMI: Roswell Park Memorial Institute  
SBAS: Stanford Brief Activity Survey  
SPPB: short physical performance battery  
STAT: Signal transducer and activator of transcription  
TGF $\beta$ : Transforming growth factor  $\beta$   
TNF $\alpha$ : tumor necrosis factor  $\alpha$   
TRL: triglyceride rich lipoprotein  
TRLP: triglyceride rich lipoprotein particle  
TUG: timed-up and go  
UMI: Unique Molecular Indices

## Tables and Figures

### Figure Legends



**Figure 1. 5-Day cell growth in the presence of complete media + 10% autologous plasma from CLL-FIT and CLL-UNFIT.** (A) OSU-CLL viable cell counts each day; (B) OSU-CLL viable percentage change from previous day; (C) Daudi viable cell counts each day; (D) Daudi viable percentage change from previous day; (E) Farage viable cell counts each day; (F) Farage viable percentage change from previous day. \* $p < 0.05$ , \*\* $p < 0.01$  different than CLL-FIT at that corresponding time point. Data are mean  $\pm$  SD.

**Figure 2. Differential expression of plasma exosomal miRNAs between CLL-FIT and CLL-UNFIT.** (A) Heat map with dendrogram illustrating correlation distance with complete linkage hierarchical clustering for the 32-exosomal miRNAs differentially expressed when comparing CLL-FIT to CLL-UNFIT. Values represent the z-score normalized miRNA counts per million reads. Colors represent the level of miRNA expression; with dark red being the highest expression and dark blue the lowest expression. (B) Volcano plot of differentially expressed miRNAs in the CLL-FIT vs. CLL-UNFIT. The p-value in  $-\log_{10}$  scale is plotted against the  $\log_2$  fold change for each miRNA, with each circle denoting an individual miRNA. The miRNAs with Wald Test p-values  $\leq 0.05$  and  $\log_2$  fold change  $\geq 1$  or  $\leq -1$  are represented by red circles (higher expression in CLL-FIT) or blue circles (higher expression in CLL-UNFIT). Nine exosomal miRNAs were higher and five were lower in the CLL-FIT compared to CLL-UNFIT group.

**Figure 3. NK-cell similarities and differences between CLL-FIT and CLL-UNFIT.** Representative flow cytometry plots of CD3 v CD56 lymphocytes for CLL-FIT (A) and CLL-UNFIT (B). (C) Absolute numbers of CD3neg/CD56+ NK-cells. (D) Percentage of lymphocytes that are CD3neg/CD56+ NK-cells. (E) Frequency of CD56dim NK-cells within the NK-cell population. (F) Frequency of CD56bright NK-cells within the NK-cell population. (G) Frequency of least differentiated NKG2A+/CD158aneg NK-cells. (H) Frequency of least differentiated NKG2A+/CD158bneg NK-cells. (I) Frequency of medium differentiated NKG2A+/CD158a+ NK-cells. (J) Frequency of medium differentiated NKG2A+/CD158b+ NK-cells. (K) Frequency of most differentiated NKG2Aneg/CD158a+ NK-cells. (L) Frequency of most differentiated NKG2Aneg/CD158b+ NK-cells. Data are mean and 95% CI.

Table 1: Demographics and Clinical Characteristics


	CLL-FIT (N=10)		CLL-UNFIT (N=10)		p-value	95% C.I.	Effect Size (d)
<b>Demographics</b>							
Age (years)	65.8	± 11.1	69.8	± 10.8	0.426	-14.3, 6.3	0.37
Sex (M/F) <sup>1</sup>	5/5		5/5		1.000		0.00
Height (cm)	167.8	± 17.0	170.8	± 11.9	0.648	-16.8, 10.7	0.20
Weight (kg)	66.2	± 16.8	85.8	± 24.1	<b>0.049</b>	-39.1, -0.1	0.94
BMI (kg/m <sup>2</sup> )	23	± 2.9	29	± 6.2	<b>0.013</b>	-10.5, -1.4	1.24
Resting Heart Rate (bpm)	68	± 12	72	± 12	0.438	-15.3, 6.9	0.33
<b>Clinical Characteristics</b>							
CLL-IPI Score	2.4	± 2.2	1.3	± 1.1	0.175	-.53, 2.74	0.63
RAI Stage [N (%)] <sup>1</sup>							
Stage 0	9 (90)		7 (70)				
Stage I	1 (10)		2 (20)		0.453		0.346
Unknown	0		1 (10)				
Disease Duration (years)	5.0	± 2.9	4.9	± 2.7	0.937	-2.5, 2.7	0.04
Cytogenetics [N (%)] <sup>1</sup>							
13q Deletion	7 (70)		5 (50)		0.361		0.20
17p Deletion	3 (30)		0		0.060		0.42
11q Deletion	2 (20)		0		0.136		0.33
Trisomy 12	0		2 (20)		0.136		0.33
TP53 Mutated	4 (40)		1 (10)		0.291		0.35
IGHV Mutated <sup>1</sup>	6 (60)		6 (60)		0.766		0.16
CD38 Expression >30% <sup>1</sup>	1 (10)		0		0.119		0.46
WBC Counts (x10 <sup>3</sup> /μL)	65	± 54	51	± 51	0.553	-35.1, 63.5	0.27
Lymphocytes	59	± 52	44	± 49	0.517	-32.7, 62.8	0.30
CD19+/CD5+ CLL-cells	48.1	± 48.6	40.8	± 41.2	0.359	-35.0, 49.7	0.16
CD4+ T-cells	1.6	± 2.3	5.1	± 7.4	0.169	-8.6, 1.6	0.64
CD8+ T-cells	0.8	± 0.9	2.2	± 2.3	0.088	-3.0, 0.2	0.80
Monocytes	1.4	± 1.4	1.8	± 2.3	0.694	-2.1, 1.5	0.21
Neutrophils	3.4	± 1.6	4.9	± 1.6	<b>0.046</b>	-3.0, -0.3	0.94
Neutrophil: T-cell	3.7	± 5.7	2.4	± 2.5	0.510	-2.2, 0.8	0.30
T-cell: Monocyte	2.1	± 1.4	6.5	± 7.6	0.086	-9.6, 0.7	0.81
Platelets (x10 <sup>3</sup> /μL)	149	± 43	196	± 62	0.065	-96.4, 3.2	0.88
Hemoglobin (g/dL)	13.0	± 1.7	13.6	± 1.5	0.433	-2.1, 0.92	0.37
β2-microglobulin (mg/dL)	1.9	± 0.7	2.4	± 0.9	0.228	-1.3, 0.33	0.57
ICAM-1 (ng/mL)	709.1	± 171.0	685.1	± 158.6	0.755	-136, 184	0.15
sCD20 (pg/mL)	220.8	± 306.9	118.2	± 181.3	0.417	-158, 364	0.40
<b>Fitness and Performance</b>							
eVO <sub>2peak</sub> (mL/kg/min)	34.2	± 3.3	24.9	± 3.2	<b>&lt;0.001</b>	6.2, 12.4	2.86
6MWT (m)	500	± 77	399	± 107	<b>0.027</b>	12.6, 188	1.08
SPPB Score	12	± 0	9.9	± 2.4	<b>0.012</b>	.52, 3.68	1.24
TUG (sec)	9.4	± 1.6	11.6	± 4.5	0.170	-5.6, 1.07	0.65
Grip Strength Right (kg)	33.3	± 12.0	32.7	± 16.7	0.930	-13.1, 14.3	0.04
Grip Strength Left (kg)	32.4	± 14.3	30.5	± 16.1	0.780	-12.4, 16.3	0.12
Best Grip (BMI normalized)	1.4	± 0.4	1.1	± 0.5	0.171	-.15, .77	0.66
IPAQ (total hours/week)	31.9	± 29.1	26.4	± 16.8	0.610	-10.2, 50.6	0.23
SBAS [N (%)] <sup>1</sup>							
Inactive	2 (20)		3 (30)				
Light	4 (40)		3 (30)				
Moderate	2 (20)		2 (20)		0.936		0.21
Hard	1 (10)		1 (10)				
Very Hard	1 (10)		1 (10)				

<sup>1</sup>Chi-square Mean ± SD. BMI (Body Mass Index); CLL-IPI (CLL- International Prognostic Index); IGHV (Immunoglobulin Heavy Chain Gene); WBC (White Blood Cell); ICAM-1 (Intercellular Adhesion Molecule 1); sCD20 (soluble CD20); 6MWD (6-Minute Walk Test); SPPB (Short Physical Performance Battery); TUG (Timed-Up And Go); IPAQ (Incidental and Planned Activity Questionnaire); SBAS (Stanford Brief Activity Survey). Continuous variables are mean ± SD, nominal data is N (%)


Table 2: Select plasma NMR measurements of systemic inflammation, insulin resistance, lipids, and lipoproteins.

	CLL-FIT	CLL-UNFIT	<i>p</i> -Value	95% C.I.	Effect Size ( <i>d</i> )
<b>Inflammation</b>					
GlycA (μmol/L)	354.7 ± 31.1	442.0 ± 97.0	<b>0.014</b>	-155.0, -19.6	1.21
<b>Insulin Resistance</b>					
LP-IR (1-100)	33.7 ± 18.1	65.7 ± 22.2	<b>0.007</b>	-54.3, -9.7	1.58
<b>Triglycerides</b>					
Total Triglycerides (mg/dL)	101.4 ± 40.6	165.2 ± 72.0	<b>0.025</b>	-118.7, 8.9	1.09
TRL Triglycerides (mg/dL)	78.1 ± 38.8	143.4 ± 67.7	<b>0.016</b>	-117.1, -13.5	1.18
Total TRLP (nmol/L)	127.6 ± 58.4	189.8 ± 70.8	<b>0.046</b>	-123.2, -1.2	0.96
Large (nmol/L)	2.5 ± 3.4	8.9 ± 6.2	<b>0.011</b>	-11.1, -1.7	1.28
Very Small (nmol/L)	73.4 ± 38.4	124.4 ± 63.7	<b>0.044</b>	-100.4, -1.6	0.97
<b>Cholesterol (mg/dL)</b>					
Total Cholesterol	194.4 ± 29.1	195.4 ± 39.4	0.949	-33.5, 31.5	0.03
TRL Cholesterol	22.5 ± 10.8	34.9 ± 13.3	<b>0.034</b>	-23.8, -1.0	1.02
LDL Cholesterol	106.3 ± 25.7	105.5 ± 29.7	0.949	-25.3, 26.9	0.03
HDL Cholesterol	65.5 ± 10.0	54.8 ± 11.6	<b>0.040</b>	0.5, 20.9	0.99
<b>HDL-P (μmol/L)</b>					
Total	24.7 ± 2.4	23.8 ± 4.2	0.559	-2.3, 4.1	0.26
Large	3.4 ± 1.4	1.9 ± 1.6	<b>0.043</b>	0.1, 2.9	1.00
<b>Lipoprotein Size (nm)</b>					
TRL	43.7 ± 4.7	50.3 ± 7.2	<b>0.027</b>	-12.3, -0.9	1.09
LDL	20.8 ± 0.4	20.4 ± 0.4	0.059	0.02, 0.8	1.00
HDL	9.2 ± 0.4	8.8 ± 0.5	0.073	-0.03, 0.8	0.88

LP-IR (Lipoprotein-Insulin Resistance); TRL (Triglyceride Rich Lipoprotein); TRLP (Triglyceride Rich Lipoprotein Particle); HDL (High Density Lipoprotein); LDL (Low-Density Lipoprotein), BCAA (Branch Chain Amino Acid). \**p*<0.05 different between CLL-FIT and CLL-UNFIT. Data are mean ± SD.




**Figure 1. 5-Day cell growth in the presence of complete media + 10% autologous plasma from CLL-FIT and CLL-UNFIT.** (A) OSU-CLL viable cell counts each day; (B) OSU-CLL viable percentage change from previous day; (C) Daudi viable cell counts each day; (D) Daudi viable percentage change from previous day; (E) Farage viable cell counts each day; (F) Farage viable percentage change from previous day. \* $p < 0.05$ , \*\* $p < 0.01$  different than CLL-FIT at that corresponding time point. Data are mean  $\pm$  SD.



**Figure 2. Differential expression of plasma exosomal miRNAs between CLL-FIT and CLL-UNFIT.** (A) Heat map with dendrogram illustrating correlation distance with complete linkage hierarchical clustering for the 32-exosomal miRNAs differentially expressed when comparing CLL-FIT to CLL-UNFIT. Values represent the z-score normalized miRNA counts per million reads. Colors represent the level of miRNA expression; with dark red being, the highest expression and dark blue the lowest expression. (B) Volcano plot of differentially expressed miRNAs in the CLL-FIT vs. CLL-UNFIT. The  $p$ -value in  $-\log_{10}$  scale is plotted against the  $\log_2$  fold change for each miRNA, with each circle denoting an individual miRNA. The miRNAs with Wald Test  $p$ -values  $\leq 0.05$  and  $\log_2$  fold change  $\geq 1$  or  $\leq -1$  are represented by red circles (higher expression in CLL-FIT) or blue circles (higher expression in CLL-UNFIT). Nine exosomal miRNAs were higher and five were lower in the CLL-FIT compared to CLL-UNFIT group.





**Figure 3. NK-cell similarities and differences between CLL-FIT and CLL-UNFIT.** Representative flow cytometry plots of CD3 v CD56 lymphocytes for (A) CLL-FIT and (B) CLL-UNFIT. (C) Absolute numbers of CD3<sup>neg</sup>/CD56<sup>+</sup> NK-cells. (D) Percentage of lymphocytes that are CD3<sup>neg</sup>/CD56<sup>+</sup> NK-cells. (E) Frequency of CD56<sup>dim</sup> NK-cells within the NK-cell population. (F) Frequency of CD56<sup>bright</sup> NK-cells within the NK-cell population. (G) Frequency of least differentiated NKG2A<sup>+</sup>/CD158a<sup>neg</sup> NK-cells. (H) Frequency of least differentiated NKG2A<sup>+</sup>/CD158b<sup>neg</sup> NK-cells. (I) Frequency of medium differentiated NKG2A<sup>+</sup>/CD158a<sup>+</sup> NK-cells. (J) Frequency of medium differentiated NKG2A<sup>+</sup>/CD158b<sup>+</sup> NK-cells. (K) Frequency of most differentiated NKG2A<sup>neg</sup>/CD158a<sup>+</sup> NK-cells. (L) Frequency of most differentiated NKG2A<sup>neg</sup>/CD158b<sup>+</sup> NK-cells. Data are mean and 95% CI.

Supplementary Table 1. Complete List of miRNAs identified.

miRNA	log2 Fold Change (CLL-FIT/CLL- UNFIT)	Log2 Fold (S.E.)	Wald Test Statistic	Wald Test p value
hsa-mir-101-2-3p	-0.983875786	0.36716	-2.679722209	0.0074
hsa-mir-199a-1-3p	0.88129529	0.33034	2.667857739	0.0076
hsa-mir-199a-2-3p	0.88129529	0.33034	2.667857739	0.0076
hsa-mir-199b-3p	0.88129529	0.33034	2.667857739	0.0076
hsa-mir-101-1-3p	-0.971037046	0.37353	-2.599613693	0.0093
hsa-mir-378a-3p	-2.282514775	0.90012	-2.535796826	0.0112
hsa-mir-32-5p	-2.470054298	0.98256	-2.513902987	0.0119
hsa-mir-24-1-3p	0.758239422	0.30543	2.482527222	0.013
hsa-mir-24-2-3p	0.758239422	0.30543	2.482527222	0.013
hsa-mir-130b-5p	2.702963742	1.09236	2.474433631	0.0133
hsa-mir-744-5p	0.966822005	0.39263	2.462433206	0.0138
hsa-mir-1301-3p	3.145610151	1.31455	2.392918164	0.0167
hsa-mir-328-3p	1.608130759	0.68509	2.347339234	0.0189
hsa-mir-4433b-3p	3.13815109	1.3475	2.328873325	0.0199
hsa-mir-4433b-5p	1.388521901	0.60249	2.304643691	0.0212
hsa-mir-383-5p	5.668882623	2.47465	2.29078449	0.022
hsa-mir-29c-3p	-1.069640841	0.47632	-2.245652119	0.0247
hsa-mir-16-1-5p	-0.727284521	0.33597	-2.164725857	0.0304
hsa-mir-16-2-5p	-0.727284521	0.33597	-2.164725857	0.0304
hsa-mir-151a-5p	0.97675396	0.45355	2.153560989	0.0313
hsa-let-7f-1-5p	-0.635424076	0.29586	-2.147697168	0.0317
hsa-mir-19b-1-3p	-0.998943501	0.46834	-2.132966674	0.0329
hsa-mir-19b-2-3p	-0.994104722	0.46627	-2.132056046	0.033
hsa-mir-183-5p	-1.020194315	0.48043	-2.123496223	0.0337
hsa-mir-451a	-0.885223579	0.42546	-2.080613285	0.0375
hsa-mir-324-3p	3.34659127	1.63312	2.049206459	0.0404
hsa-let-7f-2-5p	-0.590170504	0.2884	-2.046353137	0.0407
hsa-mir-151a-3p	0.582577816	0.28579	2.038501319	0.0415
hsa-mir-576-5p	-1.062177535	0.52628	-2.018270367	0.0436
hsa-mir-6772-3p	5.973170484	2.96149	2.016948525	0.0437
hsa-mir-182-5p	-0.837563539	0.4247	-1.97212436	0.0486
hsa-mir-1296-5p	3.726897256	1.89014	1.971759554	0.0486
hsa-mir-142-5p	-0.752124146	0.38777	-1.939613632	0.0524
hsa-mir-15a-5p	-0.71711871	0.37039	-1.936142158	0.0529
hsa-mir-96-5p	-1.314855247	0.68199	-1.927956332	0.0539
hsa-mir-1307-3p	0.837645679	0.44225	1.894057784	0.0582
hsa-let-7g-5p	-0.569977944	0.30771	-1.852294927	0.064
hsa-let-7a-1-5p	-0.531267809	0.29274	-1.814835503	0.0695
hsa-let-7a-2-5p	-0.531267809	0.29274	-1.814835503	0.0695
hsa-let-7a-3-5p	-0.531267809	0.29274	-1.814835503	0.0695
hsa-mir-339-5p	0.51066174	0.28264	1.806736469	0.0708
hsa-mir-199a-1-5p	1.975049998	1.09976	1.795891286	0.0725
hsa-mir-199a-2-5p	1.975049998	1.09976	1.795891286	0.0725
hsa-mir-191-5p	0.426561535	0.24535	1.738602443	0.0821
hsa-mir-29a-3p	-1.226522299	0.71389	-1.71808784	0.0858

hsa-mir-584-5p	0.60666997	0.35924	1.688734072	0.0913
hsa-mir-139-3p	0.936260741	0.55753	1.679300781	0.0931
hsa-mir-140-5p	1.24689876	0.75116	1.659954468	0.0969
hsa-mir-20b-5p	-0.934883701	0.56733	-1.647852597	0.0994
hsa-mir-223-3p	0.541384276	0.32938	1.643647946	0.1002
hsa-mir-3064-5p	3.89556136	2.38492	1.633417269	0.1024
hsa-mir-500a-3p	-1.126655578	0.7024	-1.604006715	0.1087
hsa-mir-10a-5p	-0.651213235	0.40674	-1.601036544	0.1094
hsa-mir-331-5p	4.73880117	2.96803	1.5966131	0.1104
hsa-mir-629-3p	-4.244348122	2.67072	-1.58921359	0.112
hsa-mir-664b-3p	-4.017289695	2.53324	-1.585833248	0.1128
hsa-mir-1291	-1.661940698	1.0522	-1.579492975	0.1142
hsa-mir-2355-3p	4.149533168	2.65535	1.562703966	0.1181
hsa-mir-6738-5p	4.463026457	2.97042	1.502491583	0.133
hsa-mir-133a-1-3p	2.136473363	1.42483	1.499454912	0.1338
hsa-mir-133a-2-3p	2.136473363	1.42483	1.499454912	0.1338
hsa-mir-142-3p	0.349845229	0.23339	1.498971514	0.1339
hsa-mir-483-5p	1.566411423	1.05549	1.484057072	0.1378
hsa-mir-5187-5p	1.805291799	1.21942	1.480456208	0.1388
hsa-mir-221-3p	0.492404648	0.33451	1.471998366	0.141
hsa-mir-143-3p	0.568444726	0.38817	1.464415718	0.1431
hsa-mir-30e-3p	-0.780048649	0.53283	-1.463969616	0.1432
hsa-mir-140-3p	-0.47168392	0.32297	-1.460475962	0.1442
hsa-mir-30a-5p	-0.592087769	0.40836	-1.449904436	0.1471
hsa-mir-181a-2-5p	-0.440722775	0.30479	-1.445981503	0.1482
hsa-mir-664b-5p	1.857625403	1.28671	1.443704221	0.1488
hsa-mir-660-5p	-0.731350959	0.50937	-1.435785567	0.1511
hsa-let-7g-3p	-4.240436069	2.95536	-1.434828286	0.1513
hsa-mir-505-5p	1.504533296	1.04949	1.433586627	0.1517
hsa-mir-1299	-2.015661936	1.41262	-1.42689401	0.1536
hsa-mir-320a	0.324779735	0.23536	1.379916189	0.1676
hsa-mir-4732-5p	-1.479082901	1.08592	-1.362057497	0.1732
hsa-mir-497-5p	-2.155441964	1.59736	-1.349377501	0.1772
hsa-mir-484	-0.603713321	0.44876	-1.345283012	0.1785
hsa-mir-93-5p	-0.35842289	0.26817	-1.336566345	0.1814
hsa-mir-3164	3.898097408	2.93199	1.329504889	0.1837
hsa-let-7b-5p	-0.487144465	0.36684	-1.327949971	0.1842
hsa-mir-651-5p	-2.649315881	1.99809	-1.325924204	0.1849
hsa-mir-144-3p	-0.70339845	0.53144	-1.323582713	0.1856
hsa-mir-27a-3p	-0.687787587	0.52055	-1.321266032	0.1864
hsa-mir-21-5p	-0.577539264	0.44548	-1.296437372	0.1948
hsa-mir-144-5p	-0.61077933	0.48262	-1.265560243	0.2057
hsa-mir-5010-3p	-3.74838597	2.96791	-1.262971665	0.2066
hsa-let-7c-5p	0.441837838	0.35343	1.25015088	0.2112
hsa-mir-3158-1-3p	-1.459726023	1.17272	-1.244738177	0.2132
hsa-mir-3158-2-3p	-1.459726023	1.17272	-1.244738177	0.2132
hsa-mir-1307-5p	1.200211251	0.96749	1.240547475	0.2148
hsa-mir-1287-5p	1.608184763	1.30476	1.232548282	0.2177
hsa-mir-376c-3p	-1.342712173	1.1127	-1.20671296	0.2275

hsa-mir-3200-3p	3.103176477	2.57273	1.206181625	0.2277
hsa-mir-181d-5p	1.99394513	1.66279	1.199156094	0.2305
hsa-mir-25-3p	-0.3641706	0.30582	-1.19081383	0.2337
hsa-mir-570-3p	-2.857004846	2.40372	-1.188576114	0.2346
hsa-mir-15b-3p	0.903633226	0.76148	1.186675883	0.2354
hsa-mir-362-5p	1.637914238	1.38069	1.186304002	0.2355
hsa-mir-31-5p	-2.703802932	2.27987	-1.185943668	0.2356
hsa-mir-30b-5p	-0.607985789	0.52084	-1.167324952	0.2431
hsa-mir-212-3p	3.463673702	2.98396	1.16076351	0.2457
hsa-mir-486-2-5p	-0.493572567	0.42601	-1.158604844	0.2466
hsa-mir-491-5p	0.81073414	0.70616	1.148089643	0.2509
hsa-let-7d-3p	1.001751966	0.87309	1.147369578	0.2512
hsa-mir-150-3p	-3.388448154	2.9711	-1.140470677	0.2541
hsa-mir-203a-3p	-2.667249535	2.3567	-1.131772687	0.2577
hsa-mir-6858-5p	1.584063222	1.40565	1.126928019	0.2598
hsa-mir-5698	3.343729312	2.97406	1.124296149	0.2609
hsa-mir-423-3p	0.336591286	0.2994	1.124202189	0.2609
hsa-mir-1294	-1.042776142	0.93021	-1.121016389	0.2623
hsa-mir-3064-3p	3.333949929	2.98636	1.116393602	0.2643
hsa-mir-3180-2	3.331709622	2.98639	1.115630111	0.2646
hsa-mir-3180-4	3.331709622	2.98639	1.115630111	0.2646
hsa-mir-3180-5	3.331709622	2.98639	1.115630111	0.2646
hsa-mir-92a-2-3p	-0.449038872	0.40295	-1.114385426	0.2651
hsa-mir-766-5p	3.323130745	2.98653	1.112706431	0.2658
hsa-let-7d-5p	-0.332395837	0.30114	-1.103797346	0.2697
hsa-mir-23a-3p	0.284144706	0.2588	1.09793917	0.2722
hsa-mir-190b	-1.968724688	1.79362	-1.097623767	0.2724
hsa-mir-335-3p	-1.029920973	0.93958	-1.096152013	0.273
hsa-mir-99b-3p	2.194749348	2.00433	1.095003674	0.2735
hsa-mir-486-1-5p	-0.429168897	0.39309	-1.091781631	0.2749
hsa-mir-130b-3p	-1.127433105	1.03524	-1.089052114	0.2761
hsa-mir-3200-5p	-3.094777686	2.84561	-1.0875607	0.2768
hsa-mir-361-3p	0.419272606	0.38642	1.085020186	0.2779
hsa-mir-7704	-3.197168331	2.97314	-1.075351171	0.2822
hsa-mir-7-1-5p	-0.438229113	0.40815	-1.073699792	0.283
hsa-mir-3144-3p	3.168918061	2.97653	1.064633578	0.287
hsa-mir-374b-5p	0.990212585	0.93098	1.06362797	0.2875
hsa-mir-224-5p	0.638471575	0.60309	1.058665143	0.2898
hsa-mir-585-3p	-3.141012384	2.97379	-1.056231652	0.2909
hsa-mir-128-2-3p	0.372999753	0.35386	1.054078666	0.2918
hsa-mir-629-5p	0.428326695	0.40673	1.053088705	0.2923
hsa-mir-340-5p	0.589314566	0.56054	1.051338137	0.2931
hsa-mir-3150b-3p	-3.125661517	2.97397	-1.051005013	0.2933
hsa-mir-4732-3p	-0.903155739	0.86624	-1.04261025	0.2971
hsa-mir-28-3p	0.370397656	0.3561	1.040152227	0.2983
hsa-mir-128-1-3p	0.353124571	0.34101	1.035521935	0.3004
hsa-mir-363-3p	-0.575093262	0.55593	-1.034476739	0.3009
hsa-mir-15b-5p	-0.30785793	0.29798	-1.033151978	0.3015
hsa-mir-181a-1-5p	-0.298280161	0.29018	-1.027924817	0.304

hsa-mir-92a-1-3p	-0.410013596	0.40209	-1.019708428	0.3079
hsa-mir-28-5p	-2.16503415	2.12925	-1.016806371	0.3092
hsa-mir-532-5p	-0.360212089	0.36018	-1.000086417	0.3173
hsa-mir-7-2-5p	-0.404392394	0.40799	-0.991174288	0.3216
hsa-mir-7-3-5p	-0.404392394	0.40799	-0.991174288	0.3216
hsa-mir-433-3p	2.941873896	2.99348	0.982759389	0.3257
hsa-mir-548ac	2.901867296	2.99432	0.969123648	0.3325
hsa-mir-196b-5p	-0.359039909	0.37849	-0.94860875	0.3428
hsa-mir-19a-3p	-0.557186371	0.59016	-0.9441336	0.3451
hsa-mir-1-1-3p	1.622975393	1.72304	0.941927949	0.3462
hsa-mir-1-2-3p	1.622975393	1.72304	0.941927949	0.3462
hsa-mir-939-5p	2.524382984	2.68058	0.941731891	0.3463
hsa-mir-548u	2.812373096	2.99628	0.938622394	0.3479
hsa-mir-185-3p	2.797473071	2.99661	0.933544498	0.3505
hsa-mir-424-5p	-1.249246606	1.38992	-0.898790946	0.3688
hsa-mir-107	-0.300912229	0.33522	-0.8976575	0.3694
hsa-mir-1288-3p	-2.656902516	2.98059	-0.891402027	0.3727
hsa-mir-320b-1	0.670591588	0.76095	0.881260057	0.3782
hsa-mir-320b-2	0.670591588	0.76095	0.881260057	0.3782
hsa-mir-3150a-5p	2.627042004	2.99993	0.875700119	0.3812
hsa-mir-30e-5p	-0.294007045	0.33702	-0.872376567	0.383
hsa-mir-206	1.569659152	1.79942	0.872315899	0.383
hsa-mir-324-5p	0.573213858	0.6609	0.867328367	0.3858
hsa-mir-509-1-3p	2.584370053	3.00063	0.861276983	0.3891
hsa-mir-509-2-3p	2.584370053	3.00063	0.861276983	0.3891
hsa-mir-509-3-3p	2.584370053	3.00063	0.861276983	0.3891
hsa-mir-26b-5p	-0.203933619	0.23689	-0.860871156	0.3893
hsa-mir-4746-5p	2.523122144	2.94426	0.856963108	0.3915
hsa-mir-122-5p	0.420232104	0.49261	0.853066388	0.3936
hsa-mir-222-3p	-0.446158492	0.5258	-0.848539811	0.3961
hsa-mir-3605-3p	1.535718265	1.81091	0.848038263	0.3964
hsa-mir-4747-5p	2.531115247	3.00152	0.843278364	0.3991
hsa-mir-636	2.531115247	3.00152	0.843278364	0.3991
hsa-mir-18a-5p	-0.655981756	0.78577	-0.834822631	0.4038
hsa-mir-326	-1.87474568	2.24649	-0.834522137	0.404
hsa-mir-7976	1.345429717	1.61339	0.833915221	0.4043
hsa-mir-1270	0.89190461	1.08908	0.818951324	0.4128
hsa-mir-106b-3p	-0.24391259	0.30189	-0.807948878	0.4191
hsa-mir-485-3p	0.960213735	1.19613	0.802767715	0.4221
hsa-mir-487a-3p	2.404471201	3.00377	0.800484584	0.4234
hsa-mir-1180-3p	-0.603673575	0.76323	-0.790944611	0.429
hsa-mir-345-5p	-0.618622023	0.78307	-0.789995676	0.4295
hsa-mir-516a-1-5p	2.346562509	3.00486	0.78092162	0.4348
hsa-mir-516a-2-5p	2.346562509	3.00486	0.78092162	0.4348
hsa-mir-423-5p	0.265452449	0.34008	0.780554926	0.4351
hsa-mir-654-3p	0.517190245	0.66347	0.779520054	0.4357
hsa-mir-7977	-2.323465293	2.98676	-0.777920908	0.4366
hsa-mir-146a-5p	0.292640558	0.37764	0.774918786	0.4384
hsa-mir-625-3p	-0.614544092	0.79599	-0.772048374	0.4401



hsa-mir-4661-5p	-2.298807596	2.98728	-0.769532633	0.4416
hsa-mir-483-3p	-2.298807596	2.98728	-0.769532633	0.4416
hsa-mir-29c-5p	-1.414377183	1.85754	-0.761426398	0.4464
hsa-mir-4326	-2.235956155	2.98863	-0.748154401	0.4544
hsa-mir-185-5p	-0.230168037	0.30844	-0.746243938	0.4555
hsa-mir-126-5p	-0.243199403	0.32662	-0.744602978	0.4565
hsa-mir-769-5p	-0.509823028	0.69264	-0.736058567	0.4617
hsa-mir-3681-5p	-2.193899418	2.98957	-0.733852009	0.463
hsa-mir-190a-5p	-0.352988191	0.48208	-0.732224631	0.464
hsa-mir-331-3p	1.051371835	1.43746	0.73141018	0.4645
hsa-mir-655-3p	-2.173515652	2.99003	-0.726920888	0.4673
hsa-mir-365a-3p	-1.306469462	1.80288	-0.724658675	0.4687
hsa-mir-365b-3p	-1.306469462	1.80288	-0.724658675	0.4687
hsa-mir-4446-3p	1.123634877	1.55339	0.723345334	0.4695
hsa-mir-93-3p	0.5497286	0.76406	0.719487353	0.4718
hsa-mir-154-5p	-1.02578571	1.42638	-0.719152417	0.472
hsa-mir-199b-5p	1.21151662	1.70902	0.708893628	0.4784
hsa-mir-873-5p	-2.097533195	2.96756	-0.706819739	0.4797
hsa-mir-99b-5p	0.246843379	0.34967	0.705937336	0.4802
hsa-mir-17-3p	-1.232787866	1.75814	-0.7011893	0.4832
hsa-mir-4678	-2.083543348	2.99216	-0.696334902	0.4862
hsa-mir-210-3p	0.865804118	1.25034	0.692457356	0.4887
hsa-mir-4742-5p	-2.071435596	2.99245	-0.692219883	0.4888
hsa-mir-34a-5p	-0.64929074	0.93959	-0.691039862	0.4895
hsa-mir-320c-1	0.426691848	0.6187	0.689659109	0.4904
hsa-mir-320c-2	0.426691848	0.6187	0.689659109	0.4904
hsa-mir-548j-3p	2.067843758	3.00938	0.68713178	0.492
hsa-mir-6758-5p	-2.036290668	2.99333	-0.680276751	0.4963
hsa-mir-10b-5p	-0.284500404	0.41887	-0.679207531	0.497
hsa-mir-181c-5p	-0.945489968	1.39344	-0.678529961	0.4974
hsa-mir-152-3p	0.439566519	0.6494	0.676884471	0.4985
hsa-mir-3127-3p	-2.02151234	2.9937	-0.675255373	0.4995
hsa-mir-5009-5p	-2.02151234	2.9937	-0.675255373	0.4995
hsa-mir-155-5p	-0.355229215	0.52646	-0.674756468	0.4998
hsa-mir-6503-5p	2.016471232	3.0103	0.669856871	0.5029
hsa-mir-1273h-3p	0.488230451	0.738	0.661554526	0.5083
hsa-mir-30d-5p	0.126095871	0.1911	0.659850732	0.5093
hsa-mir-501-3p	0.29483556	0.44858	0.657260419	0.511
hsa-mir-98-5p	-0.340355867	0.51904	-0.655746369	0.512
hsa-mir-184	1.046798261	1.60452	0.652404597	0.5141
hsa-mir-136-3p	-0.913442197	1.40313	-0.651004939	0.515
hsa-mir-598-3p	0.386072442	0.59872	0.644834766	0.519
hsa-mir-671-5p	-0.483400253	0.7523	-0.642565823	0.5205
hsa-mir-4742-3p	-1.883028381	2.95101	-0.638095667	0.5234
hsa-mir-503-5p	-1.010920657	1.60432	-0.630125956	0.5286
hsa-mir-590-3p	0.666525031	1.0589	0.629451142	0.5291
hsa-mir-21-3p	-1.343827722	2.14787	-0.625656698	0.5315
hsa-mir-342-3p	0.192250854	0.31149	0.61719589	0.5371
hsa-mir-126-3p	0.145621426	0.23645	0.615860607	0.538

hsa-mir-205-5p	0.485862517	0.79004	0.614981276	0.5386
hsa-mir-652-3p	-0.412189548	0.67076	-0.614514755	0.5389
hsa-mir-22-3p	-0.161893383	0.26391	-0.613435696	0.5396
hsa-mir-589-5p	-0.402217999	0.65774	-0.611516078	0.5409
hsa-mir-23b-3p	0.192870153	0.32039	0.601980524	0.5472
hsa-mir-27a-5p	0.418094296	0.69747	0.599446085	0.5489
hsa-mir-369-5p	0.609073747	1.02336	0.595171205	0.5517
hsa-mir-181b-1-5p	-0.389720091	0.65799	-0.592288056	0.5537
hsa-mir-329-1-3p	-0.739377762	1.27165	-0.581432077	0.5609
hsa-mir-329-2-3p	-0.739377762	1.27165	-0.581432077	0.5609
hsa-mir-221-5p	-1.724260885	2.96776	-0.580998008	0.5612
hsa-mir-148b-3p	0.173336744	0.30259	0.572845561	0.5667
hsa-let-7i-5p	-0.143058833	0.25126	-0.569357629	0.5691
hsa-mir-1306-5p	-0.79813189	1.40199	-0.569285436	0.5692
hsa-mir-664a-3p	1.087808509	1.91699	0.567455538	0.5704
hsa-mir-106b-5p	1.499065597	2.66243	0.563044657	0.5734
hsa-mir-196a-1-5p	1.408309876	2.53403	0.555758981	0.5784
hsa-mir-27b-3p	-0.195802202	0.35482	-0.55183852	0.5811
hsa-mir-1250-5p	-1.646299192	2.98377	-0.5517521	0.5811
hsa-mir-642a-3p	1.652291409	3.00404	0.55002376	0.5823
hsa-mir-486-1-3p	0.306589965	0.56971	0.538153083	0.5905
hsa-mir-486-2-3p	0.306589965	0.56971	0.538153083	0.5905
hsa-mir-411-5p	0.706681416	1.33458	0.529516604	0.5964
hsa-mir-424-3p	1.54737388	2.99936	0.515902149	0.6059
hsa-mir-194-2-5p	-0.333446997	0.64684	-0.515505336	0.6062
hsa-mir-181a-1-3p	0.38633716	0.75139	0.514164653	0.6071
hsa-mir-26a-1-5p	-0.140095512	0.27326	-0.512676456	0.6082
hsa-mir-26a-2-5p	-0.140095512	0.27326	-0.512676456	0.6082
hsa-mir-192-5p	-0.207821705	0.41295	-0.503256759	0.6148
hsa-mir-379-5p	-0.264283003	0.52524	-0.503162943	0.6148
hsa-mir-3130-1-3p	0.761605981	1.52356	0.49988525	0.6172
hsa-mir-3130-2-3p	0.761605981	1.52356	0.49988525	0.6172
hsa-mir-431-5p	-0.315319536	0.63121	-0.499545504	0.6174
hsa-mir-382-5p	-0.268838559	0.54371	-0.494453534	0.621
hsa-mir-218-1-5p	-0.812220469	1.64653	-0.493293533	0.6218
hsa-mir-378d-1	-0.731975264	1.49811	-0.488599454	0.6251
hsa-mir-378d-2	-0.731975264	1.49811	-0.488599454	0.6251
hsa-mir-9-1-5p	0.357021364	0.73602	0.485069267	0.6276
hsa-mir-9-2-5p	0.357021364	0.73602	0.485069267	0.6276
hsa-mir-9-3-5p	0.357021364	0.73602	0.485069267	0.6276
hsa-mir-454-3p	-0.22147426	0.45739	-0.484211756	0.6282
hsa-mir-339-3p	0.292705242	0.60595	0.483052342	0.6291
hsa-mir-124-1-5p	-1.410974375	3.00191	-0.470025274	0.6383
hsa-mir-124-2-5p	-1.410974375	3.00191	-0.470025274	0.6383
hsa-mir-124-3-5p	-1.410974375	3.00191	-0.470025274	0.6383
hsa-mir-139-5p	-0.268734967	0.57226	-0.469603394	0.6386
hsa-mir-194-1-5p	-0.30229033	0.64538	-0.468388695	0.6395
hsa-mir-4665-5p	-1.389997878	2.97746	-0.466839797	0.6406
hsa-mir-708-5p	0.861283474	1.84652	0.466435069	0.6409

hsa-mir-218-2-5p	-0.765308463	1.64318	-0.465749458	0.6414
hsa-mir-1260b	-0.946859248	2.04054	-0.464024449	0.6426
hsa-mir-425-5p	0.10800231	0.23479	0.459997189	0.6455
hsa-mir-323a-3p	-0.801786885	1.77038	-0.45289004	0.6506
hsa-mir-3176	-1.354686904	3.01108	-0.449901175	0.6528
hsa-mir-628-3p	0.631970062	1.42557	0.44330956	0.6575
hsa-mir-628-5p	-0.484288763	1.09945	-0.440482523	0.6596
hsa-mir-33a-5p	-1.238570987	2.81385	-0.440169221	0.6598
hsa-mir-9-1-3p	0.398150802	0.908	0.438493396	0.661
hsa-mir-9-2-3p	0.398150802	0.908	0.438493396	0.661
hsa-mir-9-3-3p	0.398150802	0.908	0.438493396	0.661
hsa-mir-296-5p	0.923528743	2.11213	0.437250535	0.6619
hsa-mir-877-5p	1.273536945	2.94289	0.432750631	0.6652
hsa-mir-92b-3p	-0.855936	1.98169	-0.431921362	0.6658
hsa-mir-92b-5p	1.193293258	2.83568	0.420814447	0.6739
hsa-mir-29b-1-3p	-0.167577243	0.40243	-0.41641227	0.6771
hsa-mir-29b-2-3p	-0.167577243	0.40243	-0.41641227	0.6771
hsa-mir-450b-5p	-1.236859535	2.97925	-0.415157401	0.678
hsa-mir-378a-5p	0.590634827	1.4317	0.412540322	0.6799
hsa-mir-1185-1-5p	1.194490473	2.96794	0.402464784	0.6873
hsa-mir-1185-2-5p	1.194490473	2.96794	0.402464784	0.6873
hsa-mir-454-5p	0.535702662	1.3531	0.39590723	0.6922
hsa-mir-487b-3p	0.37265413	0.94129	0.395899116	0.6922
hsa-mir-4723-5p	-1.188198733	3.0152	-0.394070179	0.6935
hsa-mir-204-5p	-0.535268441	1.37993	-0.387895053	0.6981
hsa-mir-150-5p	-0.150657505	0.39161	-0.384717218	0.7004
hsa-mir-1249-3p	1.133195781	2.99028	0.378959203	0.7047
hsa-mir-548k	-0.993771957	2.66054	-0.373522078	0.7088
hsa-mir-338-3p	0.226527881	0.60706	0.373156841	0.709
hsa-mir-1271-5p	-0.488341498	1.31853	-0.370367992	0.7111
hsa-let-7e-5p	0.143747211	0.38982	0.368751661	0.7123
hsa-mir-3920	-1.101310608	3.01714	-0.365018635	0.7151
hsa-mir-548e-5p	-0.819334678	2.25696	-0.363026007	0.7166
hsa-mir-941-1	-0.182209465	0.50333	-0.36201006	0.7173
hsa-mir-941-2	-0.182209465	0.50333	-0.36201006	0.7173
hsa-mir-409-5p	0.680943702	1.8978	0.358807202	0.7197
hsa-mir-3614-5p	0.634663711	1.78804	0.354949407	0.7226
hsa-mir-493-5p	0.450477454	1.29233	0.348578557	0.7274
hsa-mir-99a-5p	0.161244153	0.46346	0.347914996	0.7279
hsa-mir-135a-1-5p	-0.626130876	1.80199	-0.347467306	0.7282
hsa-mir-135a-2-5p	-0.626130876	1.80199	-0.347467306	0.7282
hsa-mir-330-5p	-0.51422637	1.53126	-0.335818277	0.737
hsa-mir-574-3p	0.232168375	0.69746	0.332877743	0.7392
hsa-mir-409-3p	-0.152042489	0.47164	-0.322369532	0.7472
hsa-mir-125a-5p	-0.141179584	0.44694	-0.315880942	0.7521
hsa-mir-2110	0.25926009	0.82784	0.31317781	0.7541
hsa-mir-3688-1-3p	-0.75527507	2.43184	-0.310577523	0.7561
hsa-mir-3688-2-3p	-0.75527507	2.43184	-0.310577523	0.7561
hsa-mir-550a-1-3p	-0.602502493	1.99701	-0.301702576	0.7629

hsa-mir-550a-2-3p	-0.602502493	1.99701	-0.301702576	0.7629
hsa-mir-550a-3-3p	-0.602502493	1.99701	-0.301702576	0.7629
hsa-mir-197-3p	0.153398128	0.51122	0.300061307	0.7641
hsa-mir-181b-2-5p	-0.182488695	0.60921	-0.29954761	0.7645
hsa-mir-4524a-3p	-0.878056149	2.95944	-0.296696678	0.7667
hsa-mir-889-3p	0.540575376	1.83882	0.293978754	0.7688
hsa-mir-148a-3p	-0.088458099	0.30816	-0.28705654	0.7741
hsa-mir-30d-3p	-0.623222512	2.19074	-0.284480133	0.776
hsa-mir-382-3p	0.558149491	1.96525	0.284009175	0.7764
hsa-mir-377-3p	-0.731130761	2.59242	-0.282026864	0.7779
hsa-mir-30a-3p	0.350269389	1.25738	0.278570012	0.7806
hsa-mir-335-5p	0.135560436	0.48855	0.277476201	0.7814
hsa-mir-125b-2-5p	0.137698835	0.49683	0.277153886	0.7817
hsa-mir-138-2-5p	-0.787970244	2.84755	-0.276718912	0.782
hsa-mir-141-3p	-0.23308995	0.84817	-0.274813807	0.7835
hsa-mir-6721-5p	-0.767800046	2.82084	-0.272188286	0.7855
hsa-mir-195-5p	-0.25774946	0.95325	-0.270390027	0.7869
hsa-mir-374a-5p	0.170063489	0.63203	0.269073312	0.7879
hsa-mir-197-5p	-0.542442856	2.07823	-0.261012213	0.7941
hsa-mir-3124-5p	0.76407435	2.94774	0.259206695	0.7955
hsa-mir-146b-5p	0.092016672	0.35672	0.257949713	0.7964
hsa-mir-3679-5p	-0.625557179	2.43197	-0.257222016	0.797
hsa-mir-874-5p	0.616859253	2.41218	0.255726693	0.7982
hsa-mir-1179	-0.49135462	1.94469	-0.252664165	0.8005
hsa-mir-124-1-3p	0.482188186	1.92368	0.250659414	0.8021
hsa-mir-124-2-3p	0.482188186	1.92368	0.250659414	0.8021
hsa-mir-124-3-3p	0.482188186	1.92368	0.250659414	0.8021
hsa-mir-130a-3p	-0.140026631	0.56045	-0.24984708	0.8027
hsa-mir-502-3p	-0.143480548	0.57639	-0.248931044	0.8034
hsa-mir-125b-1-5p	0.120015343	0.49182	0.244022767	0.8072
hsa-mir-196a-2-5p	-0.507267291	2.0795	-0.243937598	0.8073
hsa-mir-219a-2-5p	0.712629642	2.99412	0.238009665	0.8119
hsa-mir-671-3p	0.138520892	0.59965	0.231002129	0.8173
hsa-mir-320d-2	-0.158147063	0.68634	-0.230422028	0.8178
hsa-mir-337-5p	0.239735765	1.04949	0.228430508	0.8193
hsa-mir-1908-5p	0.487563816	2.13882	0.227959557	0.8197
hsa-mir-103a-1-3p	-0.047995252	0.21299	-0.225338028	0.8217
hsa-mir-103a-2-3p	-0.047995252	0.21299	-0.225338028	0.8217
hsa-mir-501-5p	-0.535132485	2.37864	-0.22497376	0.822
hsa-mir-191-3p	0.656897604	2.94962	0.222705971	0.8238
hsa-mir-17-5p	0.081462071	0.36693	0.22201034	0.8243
hsa-mir-361-5p	0.110486771	0.50887	0.217122356	0.8281
hsa-mir-145-5p	0.131275831	0.61236	0.214375798	0.8303
hsa-mir-942-5p	-0.186949401	0.87306	-0.214131821	0.8304
hsa-mir-3913-1-5p	0.275335027	1.31443	0.209470916	0.8341
hsa-mir-3913-2-5p	0.275335027	1.31443	0.209470916	0.8341
hsa-mir-425-3p	0.208508641	1.00766	0.206923005	0.8361
hsa-mir-219a-1-5p	-0.457785372	2.23384	-0.204932418	0.8376
hsa-mir-421	0.178352646	0.88011	0.202648718	0.8394

hsa-mir-625-5p	0.165197769	0.82364	0.200571072	0.841
hsa-mir-766-3p	0.161657598	0.8352	0.193555395	0.8465
hsa-mir-30c-1-5p	0.050705336	0.26416	0.191948431	0.8478
hsa-mir-30c-2-5p	0.050705336	0.26416	0.191948431	0.8478
hsa-mir-153-1-3p	0.475025002	2.49176	0.190638363	0.8488
hsa-mir-153-2-3p	0.475025002	2.49176	0.190638363	0.8488
hsa-mir-22-5p	-0.329576949	1.73193	-0.190294096	0.8491
hsa-mir-7706	0.445336595	2.34419	0.189974285	0.8493
hsa-mir-432-5p	0.0853604	0.46819	0.182319081	0.8553
hsa-mir-323b-3p	-0.124975916	0.69286	-0.180376258	0.8569
hsa-mir-1292-5p	0.324230503	1.80178	0.179949693	0.8572
hsa-mir-18a-3p	-0.209754771	1.2203	-0.171887362	0.8635
hsa-mir-149-5p	0.331182193	1.92726	0.17184062	0.8636
hsa-mir-769-3p	0.272051837	1.61029	0.168945583	0.8658
hsa-mir-374a-3p	-0.235114845	1.47087	-0.15984794	0.873
hsa-mir-488-3p	-0.450880825	2.83283	-0.159162599	0.8735
hsa-mir-4532	0.17537398	1.11159	0.157768925	0.8746
hsa-mir-193a-5p	-0.164043026	1.06618	-0.153860555	0.8777
hsa-mir-20a-5p	-0.053223071	0.37741	-0.14102141	0.8879
hsa-mir-1343-3p	0.360156224	2.64176	0.136331803	0.8916
hsa-mir-6842-3p	-0.242853852	1.94235	-0.125030626	0.9005
hsa-mir-548j-5p	0.061951991	0.53279	0.116279214	0.9074
hsa-mir-151b	-0.151239025	1.30267	-0.116099687	0.9076
hsa-mir-137	0.145735852	1.28179	0.113696964	0.9095
hsa-mir-186-5p	-0.031917712	0.28284	-0.112848629	0.9102
hsa-mir-381-3p	0.075254128	0.6834	0.11011795	0.9123
hsa-mir-4286	0.276581114	2.51994	0.109757068	0.9126
hsa-mir-664a-5p	-0.058254704	0.57138	-0.101955132	0.9188
hsa-mir-494-3p	0.120522326	1.22566	0.098332896	0.9217
hsa-mir-3074-5p	-0.283682045	2.9451	-0.096323523	0.9233
hsa-mir-340-3p	-0.269449636	2.95168	-0.091286846	0.9273
hsa-mir-874-3p	-0.094729951	1.04442	-0.090701114	0.9277
hsa-mir-138-1-5p	0.132987358	1.53486	0.086644731	0.931
hsa-mir-127-3p	0.047398045	0.56541	0.08382895	0.9332
hsa-mir-320d-1	-0.055253658	0.70456	-0.078422617	0.9375
hsa-mir-4772-3p	0.181243176	2.95363	0.061362949	0.9511
hsa-mir-4677-3p	0.104509155	1.74255	0.059974953	0.9522
hsa-let-7i-3p	-0.136698022	2.41953	-0.056497742	0.9549
hsa-mir-1224-5p	0.098866459	1.8148	0.054477913	0.9566
hsa-mir-369-3p	-0.099758769	1.9193	-0.051976646	0.9585
hsa-mir-100-5p	0.038706289	0.78553	0.049274107	0.9607
hsa-mir-25-5p	-0.052735013	1.09626	-0.048104398	0.9616
hsa-mir-532-3p	-0.045729343	0.96097	-0.047586466	0.962
hsa-mir-485-5p	0.060698119	1.3408	0.045269914	0.9639
hsa-mir-6852-5p	0.051623902	1.33638	0.038629677	0.9692
hsa-mir-362-3p	-0.089711666	2.33758	-0.038378036	0.9694
hsa-mir-132-3p	0.055712767	1.45477	0.038296696	0.9695
hsa-mir-493-3p	0.037401333	0.97916	0.038197267	0.9695
hsa-mir-3615	-0.015525649	0.45228	-0.03432759	0.9726



hsa-mir-223-5p	0.055189522	1.76859	0.031205293	0.9751
hsa-mir-200a-3p	0.065004144	2.14037	0.030370548	0.9758
hsa-mir-200c-3p	0.029119794	1.04211	0.027943242	0.9777
hsa-mir-548o-2-3p	-0.076854899	2.93694	-0.02616832	0.9791
hsa-mir-548o-3p	-0.076854899	2.93694	-0.02616832	0.9791
hsa-mir-885-5p	-0.076264255	3.00319	-0.025394391	0.9797
hsa-mir-301a-3p	-0.019982366	0.81673	-0.024466224	0.9805
hsa-mir-129-1-5p	-0.065146793	2.90104	-0.022456342	0.9821
hsa-mir-129-2-5p	-0.065146793	2.90104	-0.022456342	0.9821
hsa-mir-505-3p	0.019771952	1.02532	0.019283729	0.9846
hsa-mir-95-3p	-0.015299354	0.83069	-0.018417537	0.9853
hsa-mir-134-5p	-0.011557542	0.64621	-0.017885187	0.9857
hsa-mir-370-3p	-0.010172104	0.62974	-0.016152858	0.9871
hsa-mir-548a-1-3p	0.018906543	2.1648	0.008733612	0.993
hsa-mir-548a-2-3p	0.018906543	2.1648	0.008733612	0.993
hsa-mir-548a-3-3p	0.018906543	2.1648	0.008733612	0.993
hsa-mir-376a-1-3p	0.003327375	1.48629	0.00223871	0.9982
hsa-mir-376a-2-3p	0.003327375	1.48629	0.00223871	0.9982

---

Supplementary Table 2: Normalized exosomal miRNA expression differences between CLL-FIT and CLL-UNFIT

miRNA	CLL-Fit	CLL-Unfit	Log2 Fold Difference (SE)	Wald Test Statistic	Wald Test <i>p</i> -value
hsa-mir-101-2-3p	358.8 ± 110.7	709.1 ± 695.3	-0.98 (0.37)	-2.68	0.0074
hsa-mir-199a (1-3p and 2-3p)	2000.1 ± 806.3	1086.1 ± 597.8	0.88 (0.33)	2.67	0.0076
hsa-mir-199b-3p	2000.1 ± 806.3	1086.1 ± 597.8	0.88 (0.33)	2.67	0.0076
hsa-mir-101-1-3p	358.8 ± 110.7	702.8 ± 699.8	-0.97 (0.37)	-2.60	0.0093
hsa-mir-378a-3p	39.3 ± 31.4	192.0 ± 353.6	-2.28 (0.90)	-2.54	0.0112
hsa-mir-32-5p	6.7 ± 8.0	38.1 ± 51.7	-2.47 (0.98)	-2.51	0.0119
hsa-mir-24 (1-3p and 2-3p)	231.5 ± 67.5	137.2 ± 69.1	0.76 (0.31)	2.48	0.013
hsa-mir-130b-5p	18.9 ± 16.0	2.9 ± 5.1	2.70 (1.09)	2.47	0.0133
hsa-mir-744-5p	275.1 ± 148.2	141.2 ± 90.8	0.97 (0.39)	2.46	0.0138
hsa-mir-1301-3p	23.2 ± 25.9	2.6 ± 5.6	3.15 (1.31)	2.39	0.0167
hsa-mir-328-3p	69.0 ± 90.2	22.6 ± 20.4	1.61 (0.69)	2.35	0.0189
hsa-mir-4433b-3p	19.3 ± 22.1	2.1 ± 3.7	3.14 (1.35)	2.33	0.0199
hsa-mir-4433b-5p	109.4 ± 88.8	41.9 ± 30.5	1.39 (0.60)	2.30	0.0212
hsa-mir-383-5p	8.2 ± 24.7	0.0 ± 0.0	5.67 (2.47)	2.29	0.022
hsa-mir-29c-3p	895.7 ± 464.6	1879.8 ± 2799.6	-1.07 (0.48)	-2.25	0.0247
hsa-mir-16 (1-5p and 2-5p)	24287.9 ± 14781.3	40209.4 ± 18457.5	-0.73 (0.34)	-2.16	0.0304
hsa-mir-151a-5p	70.8 ± 39.3	35.6 ± 30.5	0.98 (0.45)	2.15	0.0313
hsa-let-7f-1-5p	3920.2 ± 1591.7	6090.8 ± 2622.7	-0.64 (0.30)	-2.15	0.0317
hsa-mir-19b (1-3p and 2-3p)	143.2 ± 83.7	286.4 ± 318.1	-1.00 (0.47)	-2.13	0.0329
hsa-mir-183-5p	76.8 ± 64.0	156.7 ± 136.5	-1.02 (0.48)	-2.12	0.0337
hsa-mir-451a	4683.4 ± 2758.3	8650.8 ± 4511.6	-0.89 (0.43)	-2.08	0.0375
hsa-mir-324-3p	7.7 ± 15.0	0.8 ± 1.2	3.35 (1.63)	2.05	0.0404
hsa-let-7f-2-5p	4069.2 ± 1621.0	6127.0 ± 2571.2	-0.59 (0.29)	-2.05	0.0407
hsa-mir-151a-3p	2250.9 ± 610.4	1503.6 ± 788.9	0.58 (0.29)	2.04	0.0415
hsa-mir-576-5p	31.0 ± 23.4	65.8 ± 44.6	-1.06 (0.53)	-2.02	0.0436
hsa-mir-6772-3p	10.0 ± 24.2	0.0 ± 0.0	5.97 (2.96)	2.02	0.0437
hsa-mir-182-5p	366.6 ± 229.6	655.2 ± 506.6	-0.84 (0.42)	-1.97	0.0486
hsa-mir-1296-5p	6.8 ± 9.1	0.4 ± 1.3	3.73 (1.89)	1.97	0.0486

Data are mean ± SD of normalized expression values, log<sub>2</sub> fold change and SE for CLL-FIT/CLL-UNFIT.

Supplementary Table 3. miRNA target genes associated with CLL. Acquired from miRDB (<http://mirdb.org/index.html>) accessed on December 1<sup>st</sup> 2020

Exosomal hsa-miR	Expression CLL-FIT relative to CLL-UNFIT	# Target Genes	Mature miRNA	Immune	NOTCH Signaling	Tumor Suppressor Signaling			Cell Cycle Regulation		Oncogene Signaling					
						p53	BCL2	TRIM33	Cyclin	CDKs	RAS	RHO	MYC	PDGF	SRC	
378a-3p	↓	309	Yes	GZMB					CCNI2		RAB10 RAN SAR1A RAB6D RAB3C RAP1A				SHE	
32-5p		985	yes		NOTCH1	JMY	BCL2L11 MCL1	TRIM33	CCNJL CCNC CCNE2	CDK16 CDKL5 CDKNIC		CDC42 CDC42BP RHPN2 TAGAP TRIO ARHGAP24	MYCBP2			
29c-3p		1034	Yes		NOTCH1 MINAR	JMY TP53INP1 TIGAR	HRK BMF MCL1 BAK1		CCNYL1 CCNT2 CCNJ CCND2 CCNA2 CCNL2 CCNI2	CDK6	NRAS	CDC42, CDC42BP CDC42SE1 RND3 RHOTB1	MYCN	PDGFB PDGFRA	FYN	
183-5p		565	Yes		MINAR			BNIP3L	CCNB1	CDK5R1	NRAS					LCK
576-5p		1182	Yes		DLL1 NOTCH2NLA	TP53BP2 TP3INP1		BNIP3L	TRIM33	CDK6 CDK17 CDKN2B		PAK2 PAK3	MYC			
130b-5p		↑	915	Unknown				MDM4		CCND1	CDK12 CABLES2		ARHGEF6 PAK2 PAK3		PDGFR PDGFA	
1301-3p	529		Yes				PERP TRIAP1			CDK17 CDK13 CDK5RAP1 CDK6 CABLES1	HRAS NRAS	CDC42BPB RHOA				
4433b-3p	289		Unknown				TP53INP2			CDKN20						
383-5p	344		Yes				PERP									
328-3p	279		Yes	Prf1			TP53INP1						PAK6			
4433b-5p	320		Unknown							CACUL1 CABLES1						
324-3p	493		Yes				TP53INP1				KRAS			MYCT1		
6772-3p	378		Unknown											MYCN		
1296-5p	156		Yes					BCL2L15			NRAS					

Supplementary Table 4: Complete plasma NMR measurements of systemic inflammation, insulin resistance, lipids, lipoproteins, and amino acids

	CLL-FIT	CLL-UNFIT	<i>p</i> -Value	95% C.I.	Effect Size ( <i>d</i> )
<b>Inflammation</b>					
GlycA (μmol/L)	354.7 ± 31.1	442.0 ± 97.0	<b>0.014</b>	-155.0, -19.6	1.21
<b>Insulin Resistance</b>					
Glucose (mg/dL)	80.5	99.8	0.108	-43.3, 4.7	0.76
LP-IR (1-100)	33.7	65.7	<b>0.007</b>	-54.3, -9.7	1.58
<b>Triglycerides</b>					
Total Triglycerides (mg/dL)	101.4 ± 40.6	165.2 ± 72.0	<b>0.025</b>	-118.7, 8.9	1.09
TRL Triglycerides (mg/dL)	78.1 ± 38.8	143.4 ± 67.7	<b>0.016</b>	-117.1, -13.5	1.18
Total TRLP (nmol/L)	127.6 ± 58.4	189.8 ± 70.8	<b>0.046</b>	-123.2, -1.2	0.96
Very Large (nmol/L)	0.38 ± 0.24	0.70 ± 0.69	0.186	-0.8, 0.2	0.62
Large (nmol/L)	2.5 ± 3.4	8.9 ± 6.2	<b>0.011</b>	-11.1, -1.7	1.28
Medium (nmol/L)	10.9 ± 10.2	22.4 ± 16.5	0.077	-24.4, 1.4	0.84
Small (nmol/L)	40.4 ± 23.1	33.4 ± 30.3	0.568	-18.3, 32.3	0.26
Very Small (nmol/L)	73.4 ± 38.4	124.4 ± 63.7	<b>0.044</b>	-100.4, -1.6	0.97
<b>Cholesterol (mg/dL)</b>					
Total Cholesterol	194.4 ± 29.1	195.4 ± 39.4	0.949	-33.5, 31.5	0.03
TRL Cholesterol	22.5 ± 10.8	34.9 ± 13.3	<b>0.034</b>	-23.8, -1.0	1.02
LDL Cholesterol	106.3 ± 25.7	105.5 ± 29.7	0.949	-25.3, 26.9	0.03
HDL Cholesterol	65.5 ± 10.0	54.8 ± 11.6	<b>0.040</b>	0.5, 20.9	0.99
<b>HDL-P (μmol/L)</b>					
Total	24.7 ± 2.4	23.8 ± 4.2	0.559	-2.3, 4.1	0.26
Large	3.4 ± 1.4	1.9 ± 1.6	<b>0.043</b>	0.1, 2.9	1.00
Medium	5.8 ± 1.5	4.7 ± 1.4	0.109	-0.3, 2.5	0.76
Small	15.5 ± 3.1	17.2 ± 4.5	0.346	-5.3, 1.9	0.44
H7P Subspecies	0.53 ± 0.51	0.28 ± 0.37	0.228	-0.2, 0.7	0.56
H6P Subspecies	1.57 ± 1.24	0.86 ± 1.43	0.252	-0.6, 1.97	0.53
H5P Subspecies	1.34 ± 0.98	0.80 ± 0.63	0.161	-0.2, 1.3	0.66
H4P Subspecies	1.78 ± 1.09	1.61 ± 0.79	0.695	-0.72, 1.1	0.18
H3P Subspecies	4.01 ± 1.37	3.13 ± 1.82	0.238	-0.8, 2.1	0.42
H2P Subspecies	11.68 ± 2.69	13.83 ± 4.60	0.218	-5.7, 1.4	0.57
H1P Subspecies	3.84 ± 1.80	3.37 ± 1.68	0.554	-1.2, 2.1	0.27
Apolipoprotein A1 (mg/dL)	162.7 ± 16.8	146.2 ± 27.2	0.120	-4.7, 37.7	0.73
<b>LDL-P (nmol/L)</b>					
Total	1462 ± 264	1580 ± 443	0.481	-460.6, 224.6	0.32
Large	257 ± 197	194 ± 138	0.421	-96.8, 222.8	0.37
Medium	265 ± 372	134 ± 165	0.321	-139.4, 401.4	0.46
Small	940 ± 395	1251 ± 424	0.107	-696, 74	0.76
Apolipoprotein B (mg/dL)	83.2 ± 18.3	91.2 ± 22.8	0.398	-27.4, 11.4	0.39
<b>Lipoprotein Size (nm)</b>					
TRL	43.7 ± 4.7	50.3 ± 7.2	<b>0.027</b>	-12.3, -0.9	1.09
LDL	20.8 ± 0.4	20.4 ± 0.4	0.059	0.02, 0.8	1.00
HDL	9.2 ± 0.4	8.8 ± 0.5	0.073	-0.03, 0.8	0.88
<b>Amino Acids (μmol/L)</b>					
Total BCAA	344.8 ± 85.6	371.1 ± 75.3	0.475	-102, 49.4	0.33
Valine	199.7 ± 49.6	202.6 ± 26.7	0.873	-40.3, 34.5	0.07
Leucine	97.2 ± 31.8	114.7 ± 39.8	0.292	-51.4, 16.4	0.49
Isoleucine	47.9 ± 17.1	54.1 ± 18.5	0.442	-22.9, 10.5	0.35
Glycine	262.2 ± 97.2	242.2 ± 62.3	0.592	-56.7, 96.7	0.24
Alanine	412.3 ± 70.0	467.7 ± 144	0.288	-161.8, 50.9	0.49

LP-IR (Lipoprotein-Insulin Resistance); TRL (Triglyceride Rich Lipoprotein); TRLP (Triglyceride Rich Lipoprotein Particle); HDL (High Density Lipoprotein); LDL (Low-Density Lipoprotein), BCAA (Branch Chain Amino Acid).

## References

1. Rai, K.R. and P. Jain, *Chronic lymphocytic leukemia (CLL)-Then and now*. Am J Hematol, 2016. **91**(3): p. 330-40.
2. Washburn, L., *Chronic lymphocytic leukemia: the most common leukemia in adults*. Jaapa, 2011. **24**(5): p. 54-8 Quiz 59.
3. Howlader N, et al. *SEER Cancer Statistics Review, 1975-2017*, National Cancer Institute. Bethesda, MD. 2020 [cited 2020; Available from: [https://seer.cancer.gov/csr/1975\\_2017/](https://seer.cancer.gov/csr/1975_2017/)].
4. Goldin, L.R., et al., *Elevated risk of chronic lymphocytic leukemia and other indolent non-Hodgkin's lymphomas among relatives of patients with chronic lymphocytic leukemia*. Haematologica, 2009. **94**(5): p. 647-53.
5. Scarfò, L., A.J. Ferreri, and P. Ghia, *Chronic lymphocytic leukaemia*. Crit Rev Oncol Hematol, 2016. **104**: p. 169-82.
6. Shanafelt, T.D., et al., *Age at diagnosis and the utility of prognostic testing in patients with chronic lymphocytic leukemia*. Cancer, 2010. **116**(20): p. 4777-87.
7. Solomon, B.M., et al., *Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study*. J Clin Oncol, 2013. **31**(7): p. 930-7.
8. Rossi, D., et al., *Early stage chronic lymphocytic leukaemia carrying unmutated IGHV genes is at risk of recurrent infections during watch and wait*. Br J Haematol, 2008. **141**(5): p. 734-6.
9. Riches, J.C. and J.G. Gribben, *Immunomodulation and immune reconstitution in chronic lymphocytic leukemia*. Semin Hematol, 2014. **51**(3): p. 228-34.
10. Dighiero, G., et al., *Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia*. N Engl J Med, 1998. **338**(21): p. 1506-14.
11. Shustik, C., et al., *Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation*. Hematol Oncol, 1988. **6**(1): p. 7-12.
12. Goede, V., et al., *Evaluation of geriatric assessment in patients with chronic lymphocytic leukemia: Results of the CLL9 trial of the German CLL study group*. Leuk Lymphoma, 2016. **57**(4): p. 789-96.
13. Sitlinger, A., D.M. Brander, and D.B. Bartlett, *Impact of Exercise on the Immune System and Outcomes in Hematologic Malignancies*. Blood Advances, 2020. **4**(8): p. 1801-1811.
14. Streckmann, F., et al., *Exercise program improves therapy-related side-effects and quality of life in lymphoma patients undergoing therapy*. Ann Oncol, 2014. **25**(2): p. 493-9.
15. Courneya, K.S., et al., *Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients*. J Clin Oncol, 2009. **27**(27): p. 4605-12.
16. Koelwyn, G.J., et al., *Exercise-dependent regulation of the tumour microenvironment*. Nat Rev Cancer, 2017. **17**(10): p. 620-632.
17. Ngo, T.H., et al., *Effect of diet and exercise on serum insulin, IGF-I, and IGFBP-1 levels and growth of LNCaP cells in vitro (United States)*. Cancer Causes Control, 2002. **13**(10): p. 929-35.
18. Barnard, R.J., et al., *Effects of a low-fat, high-fiber diet and exercise program on breast cancer risk factors in vivo and tumor cell growth and apoptosis in vitro*. Nutr Cancer, 2006. **55**(1): p. 28-34.
19. Dethlefsen, C., et al., *Exercise regulates breast cancer cell viability: systemic training adaptations versus acute exercise responses*. Breast Cancer Res Treat, 2016. **159**(3): p. 469-79.
20. Devin, J.L., et al., *Acute high intensity interval exercise reduces colon cancer cell growth*. J Physiol, 2019. **597**(8): p. 2177-2184.
21. Rozovski, U., M.J. Keating, and Z. Estrov, *Targeting Inflammatory Pathways in Chronic Lymphocytic Leukemia*. Critical reviews in oncology/hematology, 2013. **88**(3): p. 10.1016/j.critrevonc.2013.07.011.
22. Caligaris-Cappio, F., *Inflammation, the microenvironment and chronic lymphocytic leukemia*. Haematologica, 2011. **96**(3): p. 353-355.
23. Schulz, A., et al., *Inflammatory cytokines and signaling pathways are associated with survival of primary chronic lymphocytic leukemia cells in vitro: a dominant role of CCL2*. Haematologica, 2011. **96**(3): p. 408-416.
24. Dethlefsen, C., K.S. Pedersen, and P. Hojman, *Every exercise bout matters: linking systemic exercise responses to breast cancer control*. Breast Cancer Res Treat, 2017. **162**(3): p. 399-408.
25. Hertlein, E., et al., *Characterization of a New Chronic Lymphocytic Leukemia Cell Line for Mechanistic In Vitro and In Vivo Studies Relevant to Disease*. PLOS ONE, 2013. **8**(10): p. e76607.



26. group, I.C.-I.w., *An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data*. *Lancet Oncol*, 2016. **17**(6): p. 779-790.
27. Burr, J.F., et al., *The 6-minute walk test as a predictor of objectively measured aerobic fitness in healthy working-aged adults*. *Phys Sportsmed*, 2011. **39**(2): p. 133-9.
28. Bartlett, D.B., et al., *Ten weeks of high-intensity interval walk training is associated with reduced disease activity and improved innate immune function in older adults with rheumatoid arthritis: a pilot study*. *Arthritis Res Ther*, 2018. **20**(1): p. 127.
29. Herbert, Z.T., et al., *Multisite Evaluation of Next-Generation Methods for Small RNA Quantification*. *Journal of biomolecular techniques* : JBT, 2020: p. jbt.20-3102-001.
30. Mannerström, B., et al., *Extracellular small non-coding RNA contaminants in fetal bovine serum and serum-free media*. *Scientific Reports*, 2019. **9**(1): p. 5538.
31. Karlsen, T.A., T.F. Aae, and J.E. Brinchmann, *Robust profiling of microRNAs and isomiRs in human plasma exosomes across 46 individuals*. *Scientific Reports*, 2019. **9**(1): p. 19999.
32. [http://www.bioinformatics.brabham.ac.uk/projects/trim\\_galore](http://www.bioinformatics.brabham.ac.uk/projects/trim_galore).
33. Martin, M., *Cutadapt removes adapter sequences from high-throughput sequencing reads*. 2011, 2011. **17**(1): p. 3.
34. Langmead, B., et al., *Ultrafast and memory-efficient alignment of short DNA sequences to the human genome*. *Genome Biol*, 2009. **10**(3): p. R25.
35. Kozomara, A. and S. Griffiths-Jones, *miRBase: annotating high confidence microRNAs using deep sequencing data*. *Nucleic Acids Res*, 2014. **42**(Database issue): p. D68-73.
36. Love, M.I., W. Huber, and S. Anders, *Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2*. *Genome Biol*, 2014. **15**(12): p. 550.
37. Huber, W., et al., *Orchestrating high-throughput genomic analysis with Bioconductor*. *Nat Methods*, 2015. **12**(2): p. 115-21.
38. Flores-Guerrero, J.L., et al., *Lipoprotein insulin resistance index, a high-throughput measure of insulin resistance, is associated with incident type II diabetes mellitus in the prevention of renal and vascular end-stage disease study*. *Journal of clinical lipidology*, 2019. **13**(1): p. 129-137. e1.
39. Otvos, J.D., et al., *GlycA: A Composite Nuclear Magnetic Resonance Biomarker of Systemic Inflammation*. *Clinical Chemistry*, 2015.
40. Gruppen, E.G., et al., *GlycA, a novel pro-inflammatory glycoprotein biomarker is associated with mortality: results from the PREVEND study and meta-analysis*. *Journal of internal medicine*, 2019. **286**(5): p. 596-609.
41. Shalurova, I., et al., *Lipoprotein Insulin Resistance Index: a lipoprotein particle-derived measure of insulin resistance*. *Metabolic syndrome and related disorders*, 2014. **12**(8): p. 422-429.
42. Otvos, J.D., E.J. Jeyarajah, and D.W. Bennett, *Quantification of plasma lipoproteins by proton nuclear magnetic resonance spectroscopy*. *Clin Chem*, 1991. **37**(3): p. 377-86.
43. Wolak-Dinsmore, J., et al., *A novel NMR-based assay to measure circulating concentrations of branched-chain amino acids: Elevation in subjects with type 2 diabetes mellitus and association with carotid intima media thickness*. *Clinical biochemistry*, 2018. **54**: p. 92-99.
44. McCaw, L., et al., *Low Density Lipoproteins Amplify Cytokine-signaling in Chronic Lymphocytic Leukemia Cells*. *EBioMedicine*, 2017. **15**: p. 24-35.
45. Friedman, D.R., *Lipids and Their Effects in Chronic Lymphocytic Leukemia*. *EBioMedicine*, 2017. **15**: p. 2-3.
46. Rundqvist, H., et al., *Effect of acute exercise on prostate cancer cell growth*. *PLoS One*, 2013. **8**(7): p. e67579.
47. Pedersen, L., et al., *Voluntary Running Suppresses Tumor Growth through Epinephrine- and IL-6-Dependent NK Cell Mobilization and Redistribution*. *Cell Metabolism*, 2016. **23**(3): p. 554-562.
48. Bigley, A.B., et al., *Acute exercise preferentially redeploys NK-cells with a highly-differentiated phenotype and augments cytotoxicity against lymphoma and multiple myeloma target cells*. *Brain Behav Immun*, 2014. **39**: p. 160-71.
49. Barber, J.L., et al., *Effects of regular endurance exercise on GlycA: Combined analysis of 14 exercise interventions*. *Atherosclerosis*, 2018. **277**: p. 1-6.
50. Bartlett, D.B., et al., *Association of the composite inflammatory biomarker GlycA, with exercise-induced changes in body habitus in men and women with prediabetes*. *Oxid Med Cell Longev*, 2017. **2017**: p. 12.
51. Balatti, V., Y. Pekarky, and C.M. Croce, *Role of microRNA in chronic lymphocytic leukemia onset and progression*. *J Hematol Oncol*, 2015. **8**: p. 12.

52. Yeh, C.H., R. Moles, and C. Nicot, *Clinical significance of microRNAs in chronic and acute human leukemia*. Mol Cancer, 2016. **15**(1): p. 37.
53. Braga, T.V., et al., *Evaluation of MiR-15a and MiR-16-1 as prognostic biomarkers in chronic lymphocytic leukemia*. Biomedicine & Pharmacotherapy, 2017. **92**: p. 864-869.
54. Pekarsky, Y. and C.M. Croce, *Role of miR-15/16 in CLL*. Cell Death Differ, 2015. **22**(1): p. 6-11.
55. Kaur, G., et al., *RNA-Seq profiling of deregulated miRs in CLL and their impact on clinical outcome*. Blood Cancer J, 2020. **10**(1): p. 6.
56. Balatti, V., et al., *Novel mechanisms of regulation of miRNAs in CLL*. Trends Cancer, 2016. **2**(3): p. 134-143.
57. Calin, G.A., et al., *A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia*. N Engl J Med, 2005. **353**(17): p. 1793-801.
58. Haderk, F., et al., *Extracellular vesicles in chronic lymphocytic leukemia*. Leuk Lymphoma, 2013. **54**(8): p. 1826-30.
59. Huntzinger, E. and E. Izaurralde, *Gene silencing by microRNAs: contributions of translational repression and mRNA decay*. Nature Reviews Genetics, 2011. **12**(2): p. 99-110.
60. O'Brien, J., et al., *Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation*. Frontiers in Endocrinology, 2018. **9**(402).
61. Whiteside, T.L., *Tumor-Derived Exosomes and Their Role in Cancer Progression*. Advances in clinical chemistry, 2016. **74**: p. 103-141.
62. Hayes, J., P.P. Peruzzi, and S. Lawler, *MicroRNAs in cancer: biomarkers, functions and therapy*. Trends in molecular medicine, 2014. **20**(8): p. 460-469.
63. Yeh, Y.Y., et al., *Characterization of CLL exosomes reveals a distinct microRNA signature and enhanced secretion by activation of BCR signaling*. Blood, 2015. **125**(21): p. 3297-305.
64. Bobrie, A., et al., *Exosome secretion: molecular mechanisms and roles in immune responses*. Traffic, 2011. **12**(12): p. 1659-68.
65. Nair, V.D., et al., *Sedentary and Trained Older Men Have Distinct Circulating Exosomal microRNA Profiles at Baseline and in Response to Acute Exercise*. Frontiers in Physiology, 2020. **11**(605).
66. Moussay, E., et al., *MicroRNA as biomarkers and regulators in B-cell chronic lymphocytic leukemia*. Proceedings of the National Academy of Sciences of the United States of America, 2011. **108**(16): p. 6573-6578.
67. Marcucci, G., et al., *MicroRNA expression profiling in acute myeloid and chronic lymphocytic leukaemias*. Best Pract Res Clin Haematol, 2009. **22**(2): p. 239-48.
68. Cimmino, A., et al., *miR-15 and miR-16 induce apoptosis by targeting BCL2*. Proc Natl Acad Sci U S A, 2005. **102**(39): p. 13944-9.
69. Ma, F., et al., *The microRNA miR-29 controls innate and adaptive immune responses to intracellular bacterial infection by targeting interferon- $\gamma$* . Nat Immunol, 2011. **12**(9): p. 861-9.
70. Graner, M.W., S. Schnell, and M.R. Olin, *Tumor-derived exosomes, microRNAs, and cancer immune suppression*. Semin Immunopathol, 2018. **40**(5): p. 505-515.
71. Sullivan, R.P., J.W. Leong, and T.A. Fehniger, *MicroRNA regulation of natural killer cells*. Frontiers in immunology, 2013. **4**: p. 44-44.
72. Wang, P., et al., *Identification of resting and type I IFN-activated human NK cell miRNomes reveals microRNA-378 and microRNA-30e as negative regulators of NK cell cytotoxicity*. J Immunol, 2012. **189**(1): p. 211-21.
73. Donatelli, S.S., et al., *TGF- $\beta$ -inducible microRNA-183 silences tumor-associated natural killer cells*. Proc Natl Acad Sci U S A, 2014. **111**(11): p. 4203-8.
74. Sadallah, S., et al., *Platelet-derived ectosomes reduce NK cell function*. The Journal of Immunology, 2016. **197**(5): p. 1663-1671.
75. Pesce, S., et al., *miRNAs in NK Cell-Based Immune Responses and Cancer Immunotherapy*. Frontiers in Cell and Developmental Biology, 2020. **8**(119).
76. Huergo-Zapico, L., et al., *Expansion of NK cells and reduction of NKG2D expression in chronic lymphocytic leukemia. Correlation with progressive disease*. PLoS One, 2014. **9**(10): p. e108326.
77. Forconi, F. and P. Moss, *Perturbation of the normal immune system in patients with CLL*. Blood, 2015. **126**(5): p. 573-581.
78. Zhang, M., et al., *MiR-130b promotes obesity associated adipose tissue inflammation and insulin resistance in diabetes mice through alleviating M2 macrophage polarization via repression of PPAR- $\gamma$* . Immunology Letters, 2016. **180**: p. 1-8.

79. Marsilio, S., et al., *CLL Sera Drive Maturation of Normal Monocytes to M2-like Macrophages By Direct and Indirect Mechanisms*. Blood, 2014. **124**(21): p. 1970-1970.
80. Eiring, A.M., et al., *miR-328 functions as an RNA decoy to modulate hnRNP E2 regulation of mRNA translation in leukemic blasts*. Cell, 2010. **140**(5): p. 652-65.
81. Wu, H., et al., *Overexpression of miR-4433 by suberoylanilide hydroxamic acid suppresses growth of CML cells and induces apoptosis through targeting Bcr-Abl*. J Cancer, 2019. **10**(23): p. 5671-5680.
82. Fu, X., et al., *Exosomal microRNA-32-5p induces multidrug resistance in hepatocellular carcinoma via the PI3K/Akt pathway*. J Exp Clin Cancer Res, 2018. **37**(1): p. 52.
83. Mittelbrunn, M., et al., *Unidirectional transfer of microRNA-loaded exosomes from T cells to antigen-presenting cells*. Nature communications, 2011. **2**(1): p. 1-10.
84. Kraus, W.E., et al., *Effects of the amount and intensity of exercise on plasma lipoproteins*. N Engl J Med, 2002. **347**(19): p. 1483-92.
85. Kelley, G.A., K.S. Kelley, and Z. Vu Tran, *Aerobic exercise, lipids and lipoproteins in overweight and obese adults: a meta-analysis of randomized controlled trials*. Int J Obes (Lond), 2005. **29**(8): p. 881-93.
86. Yavasoglu, I., et al., *Cholesterol Levels in Patients with Chronic Lymphocytic Leukemia*. J Natl Med Assoc, 2017. **109**(1): p. 23-27.
87. Sankanagoudar, S., et al., *Cholesterol Homeostasis in Isolated Lymphocytes: a Differential Correlation Between Male Control and Chronic Lymphocytic Leukemia Subjects*. Asian Pacific journal of cancer prevention : APJCP, 2017. **18**(1): p. 23-30.
88. Friedman, D.R., et al., *Statin use and need for therapy in chronic lymphocytic leukemia*. Leuk Lymphoma, 2010. **51**(12): p. 2295-8.
89. Wang, Y.-c., et al., *Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity*. Diabetologia, 2013. **56**(10): p. 2275-2285.
90. Zhang, J., et al., *miR-130b is a potent stimulator of hepatic very-low-density lipoprotein assembly and secretion via marked induction of microsomal triglyceride transfer protein*. American Journal of Physiology-Endocrinology and Metabolism, 2020. **318**(2): p. E262-E275.
91. Chow, S., R. Buckstein, and D.E. Spaner, *A link between hypercholesterolemia and chronic lymphocytic leukemia*. Leuk Lymphoma, 2016. **57**(4): p. 797-802.
92. Mozessohn, L., et al., *The Association of Dyslipidemia With Chronic Lymphocytic Leukemia: A Population-Based Study*. J Natl Cancer Inst, 2017. **109**(3).
93. Duggal, N.A., et al., *Can physical activity ameliorate immunosenescence and thereby reduce age-related multi-morbidity?* Nat Rev Immunol, 2019.
94. Moro-Garcia, M.A., et al., *Frequent participation in high volume exercise throughout life is associated with a more differentiated adaptive immune response*. Brain Behav Immun, 2014. **39**: p. 61-74.
95. Woods, J.A., et al., *Effects of 6 months of moderate aerobic exercise training on immune function in the elderly*. Mech Ageing Dev, 1999. **109**(1): p. 1-19.
96. Yan, H., et al., *Effect of moderate exercise on immune senescence in men*. Eur J Appl Physiol, 2001. **86**(2): p. 105-11.
97. Wang, J.S. and T.P. Weng, *Hypoxic exercise training promotes antitumour cytotoxicity of natural killer cells in young men*. Clin Sci (Lond), 2011. **121**(8): p. 343-53.
98. Bartlett, D.B. and N.A. Duggal, *Moderate physical activity is associated with increased naive: memory T-cell ratio in healthy old; potential role of IL-15*. Age and Ageing, 2020. **49**(3): p. 368-373.
99. Duggal, N.A., et al., *Major features of immunosenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood*. Aging Cell, 2018. **17**(2).
100. Wherry, E.J., *T cell exhaustion*. Nature Immunology, 2011. **12**(6): p. 492-499.
101. Wensveen, F.M., V. Jelenčić, and B. Polić, *NKG2D: A Master Regulator of Immune Cell Responsiveness*. Frontiers in Immunology, 2018. **9**(441).
102. Béziat, V., et al., *NK Cell Terminal Differentiation: Correlated Stepwise Decrease of NKG2A and Acquisition of KIRs*. PLOS ONE, 2010. **5**(8): p. e11966.
103. Krüger, K. and F.C. Mooren, *T cell homing and exercise*. Exercise immunology review, 2007. **13**: p. 37-54.
104. Perry, C., et al., *Reciprocal changes in regulatory T cells and Th17 helper cells induced by exercise in patients with chronic lymphocytic leukemia*. Leuk Lymphoma, 2012. **53**(9): p. 1807-10.